uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q17.519 | Q17 | What gene does the drug Y-39983 target? | The drug Y-39983 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: ROCK2 and ROCK1 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%y-39983%" OR LOWER(tradeNames_string) LIKE "%y-39983%" OR LOWER(drugSynonyms_string) LIKE "%y-39983%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5113', 'drugName': 'Y-39983', 'tradeNames_string': '', 'drugSynonyms_string': 'Y-39983', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'ROCK2 (ENSG00000134318), ROCK1 (ENSG00000067900)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.84 | Q17 | What gene does the drug Mm-121 target? | The drug Mm-121 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene ERBB3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mm-121%" OR LOWER(tradeNames_string) LIKE "%mm-121%" OR LOWER(drugSynonyms_string) LIKE "%mm-121%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2504', 'drugName': 'Mm-121', 'tradeNames_string': '', 'drugSynonyms_string': 'MM-121, SAR-256212', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Breast Cancer (MONDO_0007254), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Peritoneum Cancer (MONDO_0002087), Ovarian Cancer (MONDO_0008170)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'ERBB3 (ENSG00000065361)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.717 | Q17 | What gene does the drug Vrc-01Ls target? | The drug Vrc-01Ls is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CD4. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vrc-01ls%" OR LOWER(tradeNames_string) LIKE "%vrc-01ls%" OR LOWER(drugSynonyms_string) LIKE "%vrc-01ls%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2609', 'drugName': 'Vrc-01Ls', 'tradeNames_string': '', 'drugSynonyms_string': 'VRC-01LS, VRC01LS, Vrc-01ls, Vrc-hivmab080-00-ab, Vrc01ls', 'linkedDiseasesDrug_string': 'Hiv-1 Infection (EFO_0000180), Hiv Infection (EFO_0000764)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CD4 (ENSG00000010610)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1185 | Q17 | What gene does the drug Benzhydrocodone Hydrochloride target? | The drug Benzhydrocodone Hydrochloride targets 3 genes: OPRK1, OPRM1 and OPRD1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%benzhydrocodone hydrochloride%" OR LOWER(tradeNames_string) LIKE "%benzhydrocodone hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%benzhydrocodone hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3008', 'drugName': 'Benzhydrocodone Hydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'Benzhydrocodone hydrochloride, KP-201, KP201', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843), Drug Dependence (EFO_0003890)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.386 | Q17 | What gene does the drug Palonosetron Hydrochloride target? | The drug Palonosetron Hydrochloride targets the gene HTR3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%palonosetron hydrochloride%" OR LOWER(tradeNames_string) LIKE "%palonosetron hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%palonosetron hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3577', 'drugName': 'Palonosetron Hydrochloride', 'tradeNames_string': 'Aloxi, Palonosetron hydrochloride', 'drugSynonyms_string': 'Palonocetron hydrochloride, Palonosetron (as hydrochloride), Palonosetron hcl, Palonosetron hydrochloride, RS-25259-197', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Nausea (HP_0002018), Chemotherapy-Induced Nausea And Vomiting (EFO_0006911), Nausea And Vomiting (HP_0002017), Post Operative Nausea And Vomiting (EFO_0004888), Vomiting (HP_0002013)', 'yearOfFirstApproval': 2003, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1022 | Q17 | What gene does the drug Acenocoumarol target? | The drug Acenocoumarol targets the gene VKORC1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%acenocoumarol%" OR LOWER(tradeNames_string) LIKE "%acenocoumarol%" OR LOWER(drugSynonyms_string) LIKE "%acenocoumarol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2229', 'drugName': 'Acenocoumarol', 'tradeNames_string': 'Sinthrome', 'drugSynonyms_string': 'Acenocoumarin, Acenocoumarol, Mini-sintrom, NSC-760052, Nicoumalone', 'linkedDiseasesDrug_string': 'Melanoma (EFO_0000756), Recurrent Thrombophlebitis (HP_0004419), Pulmonary Embolism (EFO_0003827), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'VKORC1 (ENSG00000167397)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1689 | Q17 | What gene does the drug Tadalafil target? | The drug Tadalafil targets the gene PDE5A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tadalafil%" OR LOWER(tradeNames_string) LIKE "%tadalafil%" OR LOWER(drugSynonyms_string) LIKE "%tadalafil%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1194', 'drugName': 'Tadalafil', 'tradeNames_string': 'Adcirca, Cialis, Tadliq', 'drugSynonyms_string': 'IC-351, IC351, LY-450190, LY450190, NSC-750236, NSC-759172, Tadalafil, Tadalafil mylan, Trans-tadalafil', 'linkedDiseasesDrug_string': 'Eisenmenger Syndrome (EFO_0009200), Erectile Dysfunction (EFO_0004234), Multiple Myeloma (EFO_0001378), Cancer (MONDO_0004992), Pulmonary Hypertension (MONDO_0005149), Obesity (EFO_0001073), Pulmonary Arterial Hypertension (EFO_0001361), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Essential Hypertension (MONDO_0001134), Priapism (HP_0200023), Muscular Dystrophy (MONDO_0020121), Transposition Of The Great Arteries (MONDO_0000153), Gastroparesis (EFO_1000948), Abnormality Of Cardiovascular System Morphology (HP_0030680), Vascular Dementia (EFO_0004718), Anaplastic Astrocytoma (EFO_0002499), Congestive Heart Failure (EFO_0000373), Hypertension (EFO_0000537), Glucose Intolerance (HP_0001952), Interstitial Lung Disease (EFO_0004244), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Sexual Dysfunction (EFO_0004714), Pancreatic Carcinoma (EFO_0002618), Cushing Syndrome (EFO_0003099), Insulin Resistance (EFO_0002614), Stroke (EFO_0000712), Benign Prostatic Hyperplasia (EFO_0000284), Duchenne Muscular Dystrophy (MONDO_0010679), Systemic Scleroderma (EFO_0000717), Impotence (HP_0000802), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Raynaud Disease (EFO_1001145), Major Depressive Disorder (MONDO_0002009), Glioblastoma Multiforme (EFO_0000519), Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 2003, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE5A (ENSG00000138735)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.87 | Q17 | What gene does the drug Brimapitide target? | The drug Brimapitide is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene MAPK10. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%brimapitide%" OR LOWER(tradeNames_string) LIKE "%brimapitide%" OR LOWER(drugSynonyms_string) LIKE "%brimapitide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_504', 'drugName': 'Brimapitide, C-Terminal Acid', 'tradeNames_string': '', 'drugSynonyms_string': 'AM-111, Am-111, Brimapitide, c-terminal acid, D-jnki-1, Xg-102 c-terminal acid', 'linkedDiseasesDrug_string': 'Hearing Loss (EFO_0004238)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'MAPK10 (ENSG00000109339)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2905', 'drugName': 'Brimapitide', 'tradeNames_string': '', 'drugSynonyms_string': 'Brimapitide, Xg-102', 'linkedDiseasesDrug_string': 'Inflammation (MP_0001845)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'MAPK10 (ENSG00000109339)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1684 | Q17 | What gene does the drug Bms-741672 target? | The drug Bms-741672 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CCR2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bms-741672%" OR LOWER(tradeNames_string) LIKE "%bms-741672%" OR LOWER(drugSynonyms_string) LIKE "%bms-741672%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1495', 'drugName': 'Bms-741672', 'tradeNames_string': '', 'drugSynonyms_string': 'BMS 741672, Bms-741672, Bms741672', 'linkedDiseasesDrug_string': 'Neuropathic Pain (EFO_0005762)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CCR2 (ENSG00000121807)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.333 | Q17 | What gene does the drug Etokimab target? | The drug Etokimab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene IL33. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%etokimab%" OR LOWER(tradeNames_string) LIKE "%etokimab%" OR LOWER(drugSynonyms_string) LIKE "%etokimab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2323', 'drugName': 'Etokimab', 'tradeNames_string': '', 'drugSynonyms_string': 'ANB-020, ANB020, Anb020, Etokimab', 'linkedDiseasesDrug_string': 'Sinusitis (EFO_0007486), Asthma (MONDO_0004979), Atopic Eczema (EFO_0000274), Peanut Allergic Reaction (EFO_0007425)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'IL33 (ENSG00000137033)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.7 | Q17 | What gene does the drug Cocaine Hydrochloride target? | The drug Cocaine Hydrochloride targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cocaine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%cocaine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%cocaine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3417', 'drugName': 'Cocaine Hydrochloride', 'tradeNames_string': 'Goprelto, Numbrino', 'drugSynonyms_string': 'Cocaine hcl, Cocaine hydrochloride, Cocaine hydrochloride cii, Cocaine muriate, Cocainum muriaticum, MCV 4526, NIH 8211, NSC-25263, RX-0041-002', 'linkedDiseasesDrug_string': 'Cocaine Dependence (EFO_0002610)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.737 | Q17 | What gene does the drug Balixafortide target? | The drug Balixafortide is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CXCR4. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%balixafortide%" OR LOWER(tradeNames_string) LIKE "%balixafortide%" OR LOWER(drugSynonyms_string) LIKE "%balixafortide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1873', 'drugName': 'Balixafortide', 'tradeNames_string': '', 'drugSynonyms_string': 'Balixafortide, POL-6326, POL6326, Pol6326', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Breast Cancer (MONDO_0007254), Chronic Lymphocytic Leukemia (EFO_0000095), Myocardial Infarction (EFO_0000612), Acute Myeloid Leukemia (EFO_0000222), Myelodysplastic Syndrome (EFO_0000198), Chronic Myelogenous Leukemia (EFO_0000339)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'CXCR4 (ENSG00000121966)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.750 | Q17 | What gene does the drug Pasireotide Pamoate target? | The drug Pasireotide Pamoate targets 4 genes: SSTR2, SSTR5, SSTR3 and SSTR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pasireotide pamoate%" OR LOWER(tradeNames_string) LIKE "%pasireotide pamoate%" OR LOWER(drugSynonyms_string) LIKE "%pasireotide pamoate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6121', 'drugName': 'Pasireotide Pamoate', 'tradeNames_string': 'Signifor lar, Signifor lar kit', 'drugSynonyms_string': 'Pasireotide embonate, Pasireotide pamoate', 'linkedDiseasesDrug_string': 'Acromegaly (EFO_1001485)', 'yearOfFirstApproval': 2014, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SSTR3 (ENSG00000278195), SSTR5 (ENSG00000162009), SSTR2 (ENSG00000180616), SSTR1 (ENSG00000139874)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_6120', 'drugName': 'Pasireotide Pamoate', 'tradeNames_string': 'Signifor lar, Signifor lar kit', 'drugSynonyms_string': 'Pasireotide embonate, Pasireotide pamoate', 'linkedDiseasesDrug_string': 'Acromegaly (EFO_1001485)', 'yearOfFirstApproval': 2014, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SSTR3 (ENSG00000278195), SSTR5 (ENSG00000162009), SSTR2 (ENSG00000180616), SSTR1 (ENSG00000139874)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_6123', 'drugName': 'Pasireotide Pamoate', 'tradeNames_string': 'Signifor lar, Signifor lar kit', 'drugSynonyms_string': 'Pasireotide embonate, Pasireotide pamoate', 'linkedDiseasesDrug_string': 'Acromegaly (EFO_1001485)', 'yearOfFirstApproval': 2014, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SSTR3 (ENSG00000278195), SSTR5 (ENSG00000162009), SSTR2 (ENSG00000180616), SSTR1 (ENSG00000139874)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_6122', 'drugName': 'Pasireotide Pamoate', 'tradeNames_string': 'Signifor lar, Signifor lar kit', 'drugSynonyms_string': 'Pasireotide embonate, Pasireotide pamoate', 'linkedDiseasesDrug_string': 'Acromegaly (EFO_1001485)', 'yearOfFirstApproval': 2014, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SSTR3 (ENSG00000278195), SSTR5 (ENSG00000162009), SSTR2 (ENSG00000180616), SSTR1 (ENSG00000139874)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1414 | Q17 | What gene does the drug Motesanib target? | The drug Motesanib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 7 genes: FLT4, RET, KIT, FLT1, KDR, PDGFRB and PDGFRA | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%motesanib%" OR LOWER(tradeNames_string) LIKE "%motesanib%" OR LOWER(drugSynonyms_string) LIKE "%motesanib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4189', 'drugName': 'Motesanib', 'tradeNames_string': '', 'drugSynonyms_string': 'AMG 706, AMG-706, Motesanib', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Rectum Cancer (EFO_1000657), Breast Cancer (MONDO_0007254), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Islet Cell Tumor (EFO_0007331), Fallopian Tube Cancer (MONDO_0002158), Non-Small Cell Lung Carcinoma (EFO_0003060), Lymphoma (EFO_0000574), Thyroid Cancer (MONDO_0002108), Gastrointestinal Stromal Tumor (MONDO_0011719), Peritoneum Cancer (MONDO_0002087), Carcinoid Tumor (EFO_0004243), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Esophageal Cancer (MONDO_0007576), Lymphoproliferative Syndrome (MONDO_0016537)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'KIT (ENSG00000157404), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), RET (ENSG00000165731), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'numberLinkedTargets': 7}, {'UUID': 'DrugGeneTargets_v2_4188', 'drugName': 'Motesanib', 'tradeNames_string': '', 'drugSynonyms_string': 'AMG 706, AMG-706, Motesanib', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Rectum Cancer (EFO_1000657), Breast Cancer (MONDO_0007254), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Islet Cell Tumor (EFO_0007331), Fallopian Tube Cancer (MONDO_0002158), Non-Small Cell Lung Carcinoma (EFO_0003060), Lymphoma (EFO_0000574), Thyroid Cancer (MONDO_0002108), Gastrointestinal Stromal Tumor (MONDO_0011719), Peritoneum Cancer (MONDO_0002087), Carcinoid Tumor (EFO_0004243), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Esophageal Cancer (MONDO_0007576), Lymphoproliferative Syndrome (MONDO_0016537)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'KIT (ENSG00000157404), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), RET (ENSG00000165731), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'numberLinkedTargets': 7}, {'UUID': 'DrugGeneTargets_v2_4191', 'drugName': 'Motesanib', 'tradeNames_string': '', 'drugSynonyms_string': 'AMG 706, AMG-706, Motesanib', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Rectum Cancer (EFO_1000657), Breast Cancer (MONDO_0007254), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Islet Cell Tumor (EFO_0007331), Fallopian Tube Cancer (MONDO_0002158), Non-Small Cell Lung Carcinoma (EFO_0003060), Lymphoma (EFO_0000574), Thyroid Cancer (MONDO_0002108), Gastrointestinal Stromal Tumor (MONDO_0011719), Peritoneum Cancer (MONDO_0002087), Carcinoid Tumor (EFO_0004243), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Esophageal Cancer (MONDO_0007576), Lymphoproliferative Syndrome (MONDO_0016537)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'KIT (ENSG00000157404), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), RET (ENSG00000165731), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'numberLinkedTargets': 7}, {'UUID': 'DrugGeneTargets_v2_4190', 'drugName': 'Motesanib', 'tradeNames_string': '', 'drugSynonyms_string': 'AMG 706, AMG-706, Motesanib', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Rectum Cancer (EFO_1000657), Breast Cancer (MONDO_0007254), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Islet Cell Tumor (EFO_0007331), Fallopian Tube Cancer (MONDO_0002158), Non-Small Cell Lung Carcinoma (EFO_0003060), Lymphoma (EFO_0000574), Thyroid Cancer (MONDO_0002108), Gastrointestinal Stromal Tumor (MONDO_0011719), Peritoneum Cancer (MONDO_0002087), Carcinoid Tumor (EFO_0004243), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Esophageal Cancer (MONDO_0007576), Lymphoproliferative Syndrome (MONDO_0016537)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'KIT (ENSG00000157404), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), RET (ENSG00000165731), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'numberLinkedTargets': 7}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1751 | Q17 | What gene does the drug Cetrorelix target? | The drug Cetrorelix targets the gene GNRHR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cetrorelix%" OR LOWER(tradeNames_string) LIKE "%cetrorelix%" OR LOWER(drugSynonyms_string) LIKE "%cetrorelix%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3467', 'drugName': 'Cetrorelix Acetate', 'tradeNames_string': 'Cetrotide', 'drugSynonyms_string': 'Cetrorelix, Cetrorelix acetate, Cetrotide acetate, D-20761, NS-75A, SB-075 ACETATE', 'linkedDiseasesDrug_string': 'Polycystic Ovary Syndrome (EFO_0000660), Infertility (EFO_0000545)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GNRHR (ENSG00000109163)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3240', 'drugName': 'Cetrorelix', 'tradeNames_string': 'Cetrotide', 'drugSynonyms_string': 'Cetrorelix', 'linkedDiseasesDrug_string': 'Polycystic Ovary Syndrome (EFO_0000660), Benign Prostatic Hyperplasia (EFO_0000284), Infertility (EFO_0000545), Ovarian Hyperstimulation Syndrome (MONDO_0011972), Endometriosis (EFO_0001065), Rheumatoid Arthritis (EFO_0000685)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GNRHR (ENSG00000109163)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.457 | Q17 | What gene does the drug Gallamine Triethiodide target? | The drug Gallamine Triethiodide targets 5 genes: CHRNB1, CHRNA1, CHRND, CHRNE and CHRNG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gallamine triethiodide%" OR LOWER(tradeNames_string) LIKE "%gallamine triethiodide%" OR LOWER(drugSynonyms_string) LIKE "%gallamine triethiodide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4304', 'drugName': 'Gallamine Triethiodide', 'tradeNames_string': 'Benzcurine Iodide, Flaxedil, Gallomone Triethiodide, Relaxan', 'drugSynonyms_string': 'Benzcurine iodide, Gallamine triethiodide, Gallamini triethiodidum, Gallamone triethiodide, NSC-102690, Remyolan, Syncurarine', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.496 | Q17 | What gene does the drug Danthron target? | The drug Danthron targets the gene RXRA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%danthron%" OR LOWER(tradeNames_string) LIKE "%danthron%" OR LOWER(drugSynonyms_string) LIKE "%danthron%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2100', 'drugName': 'Danthron', 'tradeNames_string': 'Dorbane, Istizin', 'drugSynonyms_string': 'Chrysazin, Danthron, Dantron, NSC-38626, NSC-646568, Pilules vinchy n.f.', 'linkedDiseasesDrug_string': 'Constipation (HP_0002019)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'RXRA (ENSG00000186350)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1482 | Q17 | What gene does the drug Tolterodine target? | The drug Tolterodine targets 2 genes: CHRM2 and CHRM3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tolterodine%" OR LOWER(tradeNames_string) LIKE "%tolterodine%" OR LOWER(drugSynonyms_string) LIKE "%tolterodine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1507', 'drugName': 'Tolterodine', 'tradeNames_string': 'Blerone xl, Detrusitol, Detrusitol xl, Efflosomyl xl, Inconex xl, Mariosea xl, Neditol xl, Preblacon xl, Santizor xl', 'drugSynonyms_string': 'KABI 2234, KABI-2234, Tolterodine', 'linkedDiseasesDrug_string': 'Urgency Urinary Incontinence (EFO_0006865), Polyuria (HP_0000103), Overactive Bladder (EFO_1000781), Pain (EFO_0003843), Neuropathic Pain (EFO_0005762), Low Back Pain (HP_0003419), Nephrolithiasis (EFO_0004253), Urinary Incontinence (HP_0000020), Pelvic Organ Prolapse (EFO_0004710)', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM2 (ENSG00000181072), CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1506', 'drugName': 'Tolterodine', 'tradeNames_string': 'Blerone xl, Detrusitol, Detrusitol xl, Efflosomyl xl, Inconex xl, Mariosea xl, Neditol xl, Preblacon xl, Santizor xl', 'drugSynonyms_string': 'KABI 2234, KABI-2234, Tolterodine', 'linkedDiseasesDrug_string': 'Urgency Urinary Incontinence (EFO_0006865), Polyuria (HP_0000103), Overactive Bladder (EFO_1000781), Pain (EFO_0003843), Neuropathic Pain (EFO_0005762), Low Back Pain (HP_0003419), Nephrolithiasis (EFO_0004253), Urinary Incontinence (HP_0000020), Pelvic Organ Prolapse (EFO_0004710)', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM2 (ENSG00000181072), CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3302', 'drugName': 'Tolterodine Tartrate', 'tradeNames_string': 'Detrol, Detrol la, Tolterodine tartrate', 'drugSynonyms_string': 'PNU-200583E, Tolterodine l-tartrate, Tolterodine tartrate', 'linkedDiseasesDrug_string': 'Urgency Urinary Incontinence (EFO_0006865), Overactive Bladder (EFO_1000781)', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM2 (ENSG00000181072)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3301', 'drugName': 'Tolterodine Tartrate', 'tradeNames_string': 'Detrol, Detrol la, Tolterodine tartrate', 'drugSynonyms_string': 'PNU-200583E, Tolterodine l-tartrate, Tolterodine tartrate', 'linkedDiseasesDrug_string': 'Urgency Urinary Incontinence (EFO_0006865), Overactive Bladder (EFO_1000781)', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM2 (ENSG00000181072)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.291 | Q17 | What gene does the drug Sufentanil Citrate target? | The drug Sufentanil Citrate targets the gene OPRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sufentanil citrate%" OR LOWER(tradeNames_string) LIKE "%sufentanil citrate%" OR LOWER(drugSynonyms_string) LIKE "%sufentanil citrate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3984', 'drugName': 'Sufentanil Citrate', 'tradeNames_string': 'Dsuvia, Sufenta, Sufenta preservative free, Sufental, Sufentanil citrate', 'drugSynonyms_string': 'R 33800, R-33800, Sufentanil citrate, Sufentanil citrate cii', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843)', 'yearOfFirstApproval': 1984, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1817 | Q17 | What gene does the drug Silmitasertib target? | The drug Silmitasertib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CSNK2A1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%silmitasertib%" OR LOWER(tradeNames_string) LIKE "%silmitasertib%" OR LOWER(drugSynonyms_string) LIKE "%silmitasertib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5963', 'drugName': 'Silmitasertib', 'tradeNames_string': '', 'drugSynonyms_string': 'CX 4945, CX-4945, CX4945, Cx-4945, Cx-4945 free acid, Silmitasertib', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Medulloblastoma (EFO_0002939), Covid-19 (MONDO_0100096), Basal Cell Carcinoma (EFO_0004193), Cholangiocarcinoma (EFO_0005221)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CSNK2A1 (ENSG00000101266)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1986 | Q17 | What gene does the drug Methapyrilene target? | The drug Methapyrilene targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%methapyrilene%" OR LOWER(tradeNames_string) LIKE "%methapyrilene%" OR LOWER(drugSynonyms_string) LIKE "%methapyrilene%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_995', 'drugName': 'Methapyrilene', 'tradeNames_string': '', 'drugSynonyms_string': 'A 3322, A-3322, Metapyrilene, Methapyrilene, Pyrinistol, Restryl, Semikon, Sleepwell, Tenalin, Thionylan', 'linkedDiseasesDrug_string': 'Allergic Disease (MONDO_0005271)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2856', 'drugName': 'Methapyrilene Hydrochloride', 'tradeNames_string': 'Thenylene hydrochloride', 'drugSynonyms_string': 'Methapyrilene hcl, Methapyrilene hydrochloride, NSC-758410, Thenylpyramine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3194', 'drugName': 'Methapyrilene Fumarate', 'tradeNames_string': '', 'drugSynonyms_string': 'Methapyrilene fumarate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1370 | Q17 | What gene does the drug Empagliflozin target? | The drug Empagliflozin targets the gene SLC5A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%empagliflozin%" OR LOWER(tradeNames_string) LIKE "%empagliflozin%" OR LOWER(drugSynonyms_string) LIKE "%empagliflozin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6084', 'drugName': 'Empagliflozin', 'tradeNames_string': 'Bi 10773, Jardiance', 'drugSynonyms_string': 'BI 10773, BI-10773, Bi10773, Empagliflozin', 'linkedDiseasesDrug_string': "Diabetes Mellitus (EFO_0000400), Glycogen Storage Disease Due To Glucose-6-Phosphatase Deficiency (Orphanet_364), Inappropriate Adh Syndrome (EFO_1000982), Hypoglycemia (HP_0001943), Ulcerative Colitis (EFO_0000729), Cardiotoxicity (EFO_1001482), Nephrolithiasis (EFO_0004253), Ascites (HP_0001541), Idiopathic Pulmonary Arterial Hypertension (MONDO_0017147), Polycystic Ovary Syndrome (EFO_0000660), Crohn'S Disease (EFO_0000384), Acute Myocardial Infarction (EFO_0008583), Non-Alcoholic Fatty Liver Disease (EFO_0003095), Insulin Resistance (EFO_0002614), Gestational Diabetes (EFO_0004593), Myocardial Infarction (EFO_0000612), Portal Hypertension (EFO_0000666), Chronic Kidney Disease (EFO_0003884), Diabetic Nephropathy (EFO_0000401), Heart Failure (EFO_0003144), Hyponatremia (HP_0002902), Kidney Disease (EFO_0003086), Prediabetes Syndrome (EFO_1001121), Acute Kidney Injury (HP_0001919), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148), Severe Acute Respiratory Syndrome (EFO_0000694)", 'yearOfFirstApproval': 2014, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC5A2 (ENSG00000140675)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.893 | Q17 | What gene does the drug Irinotecan Hydrochloride target? | The drug Irinotecan Hydrochloride targets the gene TOP1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%irinotecan hydrochloride%" OR LOWER(tradeNames_string) LIKE "%irinotecan hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%irinotecan hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5193', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_string': 'Campto, Camptosar, Irinotecan hydrochloride, Onivyde', 'drugSynonyms_string': 'CPT-11, DQ-2805, Irinotecan hydrochloride, Irinotecan hydrochloride anhydrous, Irinotecan hydrochloride hydrate, Irinotecan hydrochloride trihydrate, Irinotecan monohydrochloride trihydrate, NSC-759878, U-101,440E, U-101440E', 'linkedDiseasesDrug_string': "Ovarian Carcinoma (EFO_0001075), Verrucous Carcinoma (EFO_0007535), Oligodendroglioma (EFO_0000632), Lung Carcinoma (EFO_0001071), Malignant Colon Neoplasm (MONDO_0021063), Pineoblastoma (EFO_1000475), Malignant Glioma (MONDO_0100342), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Carcinoma (EFO_0000313), Malt Lymphoma (EFO_0000191), Liver Cancer (MONDO_0002691), Cervical Cancer (MONDO_0002974), Osteosarcoma (EFO_0000637), Ewing Sarcoma (EFO_0000174), Lung Cancer (MONDO_0008903), Follicular Lymphoma (MONDO_0018906), Leukemia (EFO_0000565), Lymphoma, Aids-Related (EFO_1001365), Anus Cancer (MONDO_0001879), Colorectal Adenocarcinoma (EFO_0000365), Glioblastoma Multiforme (EFO_0000519), Adult T-Cell Leukemia/Lymphoma (MONDO_0019471), Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Chronic Lymphocytic Leukemia (EFO_0000095), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Neuroendocrine Carcinoma (MONDO_0002120), Gliosarcoma (EFO_1001465), Fallopian Tube Carcinoma (EFO_1000251), Mantle Cell Lymphoma (EFO_1001469), Gastric Adenocarcinoma (EFO_0000503), Basal Cell Carcinoma (EFO_0004193), Olfactory Neuroblastoma (EFO_1000407), Diffuse Large B-Cell Lymphoma (EFO_0000403), Inverted Papilloma (MONDO_0002537), Gastric Carcinoma (EFO_0000178), Anaplastic Oligodendroglioma (EFO_0002501), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Lethal Midline Granuloma (EFO_1001013), Appendix Carcinoma (MONDO_0003196), Triple-Negative Breast Cancer (EFO_0005537), Salivary Gland Cancer (MONDO_0004669), Hodgkins Lymphoma (EFO_0000183), Rectum Cancer (EFO_1000657), Merkel Cell Skin Cancer (EFO_1001471), Non-Small Cell Lung Carcinoma (EFO_0003060), Peripheral Primitive Neuroectodermal Tumor (MONDO_0018271), Neuroblastoma (EFO_0000621), Hepatoblastoma (EFO_1000292), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Anaplastic Astrocytoma (EFO_0002499), Diarrhea (HP_0002014), Breast Cancer (MONDO_0007254), Embryonal Rhabdomyosarcoma (EFO_0000437), Lymphoma (EFO_0000574), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Mycosis Fungoides (EFO_1001051), Biliary Tract Cancer (MONDO_0003060), Penile Cancer (MONDO_0001325), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Rhabdomyosarcoma (EFO_0002918), Gallbladder Cancer (MONDO_0005411), Ganglioneuroblastoma (EFO_0000502), Carcinoid Tumor (EFO_0004243), Peritoneum Cancer (MONDO_0002087), Oropharyngeal Carcinoma (MONDO_0044926), Cutaneous Melanoma (EFO_0000389), Neoplasm (EFO_0000616), Adenocarcinoma (EFO_0000228), Urinary Bladder Cancer (MONDO_0001187), Sarcoma (EFO_0000691), Grade Iii Meningioma (MONDO_0020634), Medulloblastoma (EFO_0002939), Metastatic Melanoma (EFO_0002617), Burkitts Lymphoma (EFO_0000309), Angioimmunoblastic T-Cell Lymphoma (EFO_0000255), Rectal Carcinoma (MONDO_0044937), Breast Carcinoma (EFO_0000305), Prostate Cancer (MONDO_0008315), Neutropenia (MONDO_0001475), Colorectal Neoplasm (EFO_0004142), Cerebral Astrocytoma (MONDO_0021633), Urethra Cancer (MONDO_0004192), Endometrial Carcinoma (EFO_1001512), Esophageal Cancer (MONDO_0007576), Lymphoblastic Lymphoma (MONDO_0000873), Alveolar Rhabdomyosarcoma (EFO_0000248), Renal Cell Carcinoma (EFO_0000681), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Mesenchymoma (EFO_1001042), Kidney Cancer (MONDO_0002367), Choroid Plexus Neoplasm (MONDO_0016717)", 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TOP1 (ENSG00000198900)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1063 | Q17 | What gene does the drug Isradipine target? | The drug Isradipine targets 4 genes: CACNA1C, CACNA1D, CACNA1S and CACNA1F. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%isradipine%" OR LOWER(tradeNames_string) LIKE "%isradipine%" OR LOWER(drugSynonyms_string) LIKE "%isradipine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5017', 'drugName': 'Isradipine', 'tradeNames_string': 'Dynacirc, Dynacirc cr, Isradipine, Prescal', 'drugSynonyms_string': 'Isradipine, Isrodipine, NSC-759892, PN 200-110, PN-200-110', 'linkedDiseasesDrug_string': 'Smoking Cessation (EFO_0004319), Drug Dependence (EFO_0003890), Nicotine Dependence (EFO_0003768), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Parkinson Disease (MONDO_0005180), Bipolar Disorder (MONDO_0004985), Opioid Dependence (EFO_0005611)', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1846 | Q17 | What gene does the drug Gemtuzumab Ozogamicin target? | The drug Gemtuzumab Ozogamicin targets the gene CD33. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gemtuzumab ozogamicin%" OR LOWER(tradeNames_string) LIKE "%gemtuzumab ozogamicin%" OR LOWER(drugSynonyms_string) LIKE "%gemtuzumab ozogamicin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6112', 'drugName': 'Gemtuzumab Ozogamicin', 'tradeNames_string': 'Mylotarg', 'drugSynonyms_string': 'CDP-771, CMA-676, CMC-676, Gemtuzumab ozogamicin, Gemtuzumab ozogamicin recombinant, L01XC05, WAY-CMA-676', 'linkedDiseasesDrug_string': 'Chronic Lymphocytic Leukemia (EFO_0000095), Leukemia (EFO_0000565), Neoplasm (EFO_0000616), Myeloid Leukemia (MONDO_0004643), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Myelodysplastic Syndrome (EFO_0000198), Juvenile Myelomonocytic Leukemia (EFO_1000309), Acute Promyelocytic Leukemia (EFO_0000224)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CD33 (ENSG00000105383)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1982 | Q17 | What gene does the drug Pegsunercept target? | The drug Pegsunercept is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene TNF. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pegsunercept%" OR LOWER(tradeNames_string) LIKE "%pegsunercept%" OR LOWER(drugSynonyms_string) LIKE "%pegsunercept%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2592', 'drugName': 'Pegsunercept', 'tradeNames_string': '', 'drugSynonyms_string': 'Pegsunercept, STNF-RI', 'linkedDiseasesDrug_string': 'Rheumatoid Arthritis (EFO_0000685)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'TNF (ENSG00000232810)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.789 | Q17 | What gene does the drug Guanidine Hydrochloride target? | The drug Guanidine Hydrochloride targets 40 genes: KCNB1, KCND2, KCNA7, KCNG3, KCNA4, KCNQ1, KCNQ3, KCNA1, KCNC4, KCNS1, KCNG2, KCNA6, KCNV2, KCNA5, KCNH2, KCNS3, KCNQ4, KCND3, KCNG1, KCNB2, KCNH6, KCNC3, KCNG4, KCNF1, KCNH8, KCNS2, KCNA3, KCNQ2, KCNH4, KCNA10, KCNC2, KCNC1, KCNH1, KCNH3, KCNV1, KCNQ5, KCND1, KCNA2, KCNH7 and KCNH5. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%guanidine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%guanidine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%guanidine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5118', 'drugName': 'Guanidine Hydrochloride', 'tradeNames_string': 'Guanidine hydrochloride', 'drugSynonyms_string': 'Guanidine HCl, Guanidine hydrochloride', 'linkedDiseasesDrug_string': 'Myasthenia Gravis (EFO_0004991), Small Cell Carcinoma (EFO_0008524), Muscle Weakness (HP_0001324)', 'yearOfFirstApproval': 1939, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNQ1 (ENSG00000053918), KCND3 (ENSG00000171385), KCNH2 (ENSG00000055118), KCNA2 (ENSG00000177301), KCNA1 (ENSG00000111262), KCNQ2 (ENSG00000075043), KCNQ3 (ENSG00000184156), KCNA7 (ENSG00000104848), KCNQ5 (ENSG00000185760), KCNQ4 (ENSG00000117013), KCNH1 (ENSG00000143473), KCNA4 (ENSG00000182255), KCNA5 (ENSG00000130037), KCNA3 (ENSG00000177272), KCNA6 (ENSG00000151079), KCNC1 (ENSG00000129159), KCND2 (ENSG00000184408), KCNB2 (ENSG00000182674), KCNC4 (ENSG00000116396), KCNC3 (ENSG00000131398), KCNB1 (ENSG00000158445), KCNA10 (ENSG00000143105), KCNV1 (ENSG00000164794), KCNH5 (ENSG00000140015), KCNG3 (ENSG00000171126), KCNG4 (ENSG00000168418), KCNV2 (ENSG00000168263), KCNS1 (ENSG00000124134), KCNH8 (ENSG00000183960), KCNC2 (ENSG00000166006), KCNS3 (ENSG00000170745), KCNH6 (ENSG00000173826), KCNF1 (ENSG00000162975), KCNH7 (ENSG00000184611), KCND1 (ENSG00000102057), KCNG1 (ENSG00000026559), KCNG2 (ENSG00000178342), KCNH3 (ENSG00000135519), KCNS2 (ENSG00000156486), KCNH4 (ENSG00000089558)', 'numberLinkedTargets': 40}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.866 | Q17 | What gene does the drug Oxytocin target? | The drug Oxytocin targets the gene OXTR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%oxytocin%" OR LOWER(tradeNames_string) LIKE "%oxytocin%" OR LOWER(drugSynonyms_string) LIKE "%oxytocin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5031', 'drugName': 'Oxytocin', 'tradeNames_string': 'Orasthin, Oxytocin, Pitocin, Syntocinon, Syntometrine', 'drugSynonyms_string': 'Alpha-hypophamine, Endopituitrina, Intertocine s, Oxytocin, Oxytocinum, TNX-1900, TNX1900, TTA-121', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Substance Abuse (MONDO_0002491), Hemorrhage (MP_0001914), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Obesity (EFO_0001073), Prader-Willi Syndrome (MONDO_0008300), Aging (GO_0007568), Gastroparesis (EFO_1000948), Anorexia Nervosa (MONDO_0005351), Post-Traumatic Stress Disorder (EFO_0001358), Preeclampsia (EFO_0000668), Mood Disorder (EFO_0004247), Fragile X Syndrome (MONDO_0010383), Osteoarthritis, Knee (EFO_0004616), Schizoaffective Disorder (EFO_0005411), Attention Deficit Hyperactivity Disorder (EFO_0003888), Neuropathic Pain (EFO_0005762), Cardiac Arrhythmia (EFO_0004269), Cocaine Dependence (EFO_0002610), Uterine Inertia (EFO_1001863), Autism Spectrum Disorder (EFO_0003756), Alcohol Withdrawal (EFO_0004777), Sexual Dysfunction (EFO_0004714), Memory Impairment (EFO_0001072), Obsessive-Compulsive Disorder (EFO_0004242), Dystocia (EFO_1000911), Myocardial Infarction (EFO_0000612), Inflammation (MP_0001845), Psychiatric Disorder (MONDO_0002025), Depressive Disorder (MONDO_0002050), Obstructive Sleep Apnea (EFO_0003918), Postpartum Hemorrhage (EFO_0009579), Breast Ductal Carcinoma In Situ (EFO_0000432), Alcohol Dependence (MONDO_0007079), Social Anxiety Disorder (EFO_1001917), Opioid Dependence (EFO_0005611), Sleep Apnea (EFO_0003877), Opioid Use Disorder (EFO_0010702), Frontotemporal Dementia (MONDO_0017276), Osteoarthritis (MONDO_0005178), Atrophic Vaginitis (EFO_1001271), Body Weight Gain (EFO_0004566), Chronic Pain (HP_0012532), Atrophy (EFO_1000096), Major Depressive Disorder (MONDO_0002009), Diabetes Insipidus (MONDO_0004782), Schizophrenia (MONDO_0005090), Neurodevelopmental Disorder (EFO_0010642)', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OXTR (ENSG00000180914)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1306 | Q17 | What gene does the drug Apricoxib target? | The drug Apricoxib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene PTGS2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%apricoxib%" OR LOWER(tradeNames_string) LIKE "%apricoxib%" OR LOWER(drugSynonyms_string) LIKE "%apricoxib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4674', 'drugName': 'Apricoxib', 'tradeNames_string': '', 'drugSynonyms_string': 'Apricoxib, CS-706, R-109339, TG-01, TG01', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Non-Small Cell Lung Carcinoma (EFO_0003060), Breast Cancer (MONDO_0007254)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1088 | Q17 | What gene does the drug Enalapril Maleate target? | The drug Enalapril Maleate targets the gene ACE. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%enalapril maleate%" OR LOWER(tradeNames_string) LIKE "%enalapril maleate%" OR LOWER(drugSynonyms_string) LIKE "%enalapril maleate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6274', 'drugName': 'Enalapril Maleate', 'tradeNames_string': 'Ednyt, Enalapril maleate, Enapren, Epaned, Epaned kit, Innovace, Pralenal 10, Pralenal 2.5, Pralenal 20, Pralenal 5, Renitec, Vasotec, Xanef', 'drugSynonyms_string': 'Enalapril maleate, MK-421, NSC-758143', 'linkedDiseasesDrug_string': 'Congestive Heart Failure (EFO_0000373), Preeclampsia (EFO_0000668), Intracerebral Hemorrhage (EFO_0005669), Heart Failure (EFO_0003144), Hypertension (EFO_0000537), Proteinuria (HP_0000093), Rheumatoid Arthritis (EFO_0000685)', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACE (ENSG00000159640)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1889 | Q17 | What gene does the drug Dyclonine target? | The drug Dyclonine targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dyclonine%" OR LOWER(tradeNames_string) LIKE "%dyclonine%" OR LOWER(drugSynonyms_string) LIKE "%dyclonine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2429', 'drugName': 'Dyclonine', 'tradeNames_string': '', 'drugSynonyms_string': 'Dyclonine', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_5439', 'drugName': 'Dyclonine Hydrochloride', 'tradeNames_string': 'Dyclone', 'drugSynonyms_string': 'Dyclocaine, Dyclonine HCl, Dyclonine hcl, Dyclonine hydrochloride, NSC-23018', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.331 | Q17 | What gene does the drug Moxisylyte target? | The drug Moxisylyte targets 6 genes: ADRA2A, ADRA2C, ADRA1A, ADRA1D, ADRA2B and ADRA1B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%moxisylyte%" OR LOWER(tradeNames_string) LIKE "%moxisylyte%" OR LOWER(drugSynonyms_string) LIKE "%moxisylyte%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_770', 'drugName': 'Moxisylyte', 'tradeNames_string': 'Erecnos, Moxivig', 'drugSynonyms_string': 'Acetoxythymoxamine, Carlytene, Moxisylyte, Moxisylyte hcl, Moxisylyte hydrochloride, NSC-170448, Thymoxamine, Thymoxamine hcl, Thymoxamine hydrochloride', 'linkedDiseasesDrug_string': 'Erectile Dysfunction (EFO_0004234), Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 6}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.448 | Q17 | What gene does the drug Tolbutamide target? | The drug Tolbutamide targets 2 genes: KCNJ11 and ABCC8. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tolbutamide%" OR LOWER(tradeNames_string) LIKE "%tolbutamide%" OR LOWER(drugSynonyms_string) LIKE "%tolbutamide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_427', 'drugName': 'Tolbutamide', 'tradeNames_string': 'Glyconon, Orinase, Pramidex, Rastinon, Tolbutamide', 'drugSynonyms_string': '1-butyl-3-(p-tolylsulfonyl)urea, Arkozal, Butamide, Diabetamid, Ipoglicone, NSC-23813, NSC-87833, Tolbutamide, Tolbutamidum, Willbutamide', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Cancer (MONDO_0004992), Neoplasm (EFO_0000616), Chronic Pain (HP_0012532), Serum Lipopolysaccharide Activity (EFO_0600064), Lymphoma (EFO_0000574), Chronic Hepatitis C Virus Infection (EFO_0004220), Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 1961, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNJ11 (ENSG00000187486), ABCC8 (ENSG00000006071)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3569', 'drugName': 'Tolbutamide Sodium, Sterile', 'tradeNames_string': 'Orinase diagnostic', 'drugSynonyms_string': 'Sodium tolbutamide, Tolbutamide sodium, Tolbutamide sodium salt, Tolbutamide sodium, sterile', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1961, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNJ11 (ENSG00000187486), ABCC8 (ENSG00000006071)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.766 | Q17 | What gene does the drug Testosterone Cypionate target? | The drug Testosterone Cypionate targets the gene AR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%testosterone cypionate%" OR LOWER(tradeNames_string) LIKE "%testosterone cypionate%" OR LOWER(drugSynonyms_string) LIKE "%testosterone cypionate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_434', 'drugName': 'Testosterone Cypionate', 'tradeNames_string': 'Andro-Cyp, Depandro, Depo-testosterone, Depotest, Testosterone, Testosterone cypionate', 'drugSynonyms_string': 'Depo-Testadiol, NSC-9157, Testosterone 17.beta.-cyclopentanepropionate, Testosterone cipionate, Testosterone cyclopentylpropionate, Testosterone cypionate, Testosterone cypionate ciii', 'linkedDiseasesDrug_string': 'Hypogonadism (MONDO_0002146), Prostate Cancer (MONDO_0008315), Diabetic Neuropathy (EFO_1000783), Neoplasm (EFO_0000616), Metastatic Prostate Cancer (EFO_0000196), Sexual Dysfunction (EFO_0004714), Prostate Adenocarcinoma (EFO_0000673), Orchitis (EFO_1001078)', 'yearOfFirstApproval': 1978, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1844 | Q17 | What gene does the drug Felodipine target? | The drug Felodipine targets 5 genes: CACNA1C, CACNA1F, CACNA1S, NR3C2 and CACNA1D. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%felodipine%" OR LOWER(tradeNames_string) LIKE "%felodipine%" OR LOWER(drugSynonyms_string) LIKE "%felodipine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4515', 'drugName': 'Felodipine', 'tradeNames_string': 'Cabren, Cardioplen xl, Felodipine, Felogen xl, Felotens xl, Folpik xl, Keloc sr, Neofel xl, Parmid xl, Pinefeld xl, Plendil, Preslow, Vascalpha', 'drugSynonyms_string': 'C08CA02, Felodipine, H 154/82, H-154/82, NSC-760343', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Coronary Artery Disease (EFO_0001645), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Hypercholesterolemia (HP_0003124), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914)', 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C2 (ENSG00000151623), CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_4516', 'drugName': 'Felodipine', 'tradeNames_string': 'Cabren, Cardioplen xl, Felodipine, Felogen xl, Felotens xl, Folpik xl, Keloc sr, Neofel xl, Parmid xl, Pinefeld xl, Plendil, Preslow, Vascalpha', 'drugSynonyms_string': 'C08CA02, Felodipine, H 154/82, H-154/82, NSC-760343', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Coronary Artery Disease (EFO_0001645), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Hypercholesterolemia (HP_0003124), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914)', 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C2 (ENSG00000151623), CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.913 | Q17 | What gene does the drug Histamine Phosphate target? | The drug Histamine Phosphate targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%histamine phosphate%" OR LOWER(tradeNames_string) LIKE "%histamine phosphate%" OR LOWER(drugSynonyms_string) LIKE "%histamine phosphate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2178', 'drugName': 'Histamine Phosphate', 'tradeNames_string': 'Histamine phosphate', 'drugSynonyms_string': 'Histamine phosphate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1939, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1141 | Q17 | What gene does the drug Savolitinib target? | The drug Savolitinib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene MET. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%savolitinib%" OR LOWER(tradeNames_string) LIKE "%savolitinib%" OR LOWER(drugSynonyms_string) LIKE "%savolitinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4025', 'drugName': 'Savolitinib', 'tradeNames_string': '', 'drugSynonyms_string': 'AZD-6094, AZD6094, Azd-6094, HMPL-504, Savolitinib, Volitinib', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Rectum Cancer (EFO_1000657), Urogenital Neoplasm (EFO_0003863), Prostate Cancer (MONDO_0008315), Papillary Renal Cell Carcinoma (EFO_0000640), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Gastric Adenocarcinoma (EFO_0000503), Non-Small Cell Lung Carcinoma (EFO_0003060), Renal Cell Carcinoma (EFO_0000681), Colon Adenocarcinoma (EFO_1001949), Carcinoma (EFO_0000313), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'MET (ENSG00000105976)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.180 | Q17 | What gene does the drug Huj591 111In target? | The drug Huj591 111In is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene FOLH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%huj591 111in%" OR LOWER(tradeNames_string) LIKE "%huj591 111in%" OR LOWER(drugSynonyms_string) LIKE "%huj591 111in%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4279', 'drugName': 'Huj591 111In', 'tradeNames_string': '', 'drugSynonyms_string': 'HUJ591, Huj591 (111in), Huj591 111in', 'linkedDiseasesDrug_string': 'Prostate Cancer (MONDO_0008315)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'FOLH1 (ENSG00000086205)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.729 | Q17 | What gene does the drug Benzphetamine Hydrochloride target? | The drug Benzphetamine Hydrochloride targets 2 genes: SLC6A2 and SLC18A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%benzphetamine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%benzphetamine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%benzphetamine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_167', 'drugName': 'Benzphetamine Hydrochloride', 'tradeNames_string': 'Benzphetamine hydrochloride, Didrex', 'drugSynonyms_string': 'Benzfetamine hydrochloride, Benzphetamine chloride, Benzphetamine hcl, Benzphetamine hydrochloride, Benzphetamine hydrochloride ciii, NSC-10937, U-0441', 'linkedDiseasesDrug_string': 'Obesity (EFO_0001073)', 'yearOfFirstApproval': 1960, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC18A2 (ENSG00000165646)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_168', 'drugName': 'Benzphetamine Hydrochloride', 'tradeNames_string': 'Benzphetamine hydrochloride, Didrex', 'drugSynonyms_string': 'Benzfetamine hydrochloride, Benzphetamine chloride, Benzphetamine hcl, Benzphetamine hydrochloride, Benzphetamine hydrochloride ciii, NSC-10937, U-0441', 'linkedDiseasesDrug_string': 'Obesity (EFO_0001073)', 'yearOfFirstApproval': 1960, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC18A2 (ENSG00000165646)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1273 | Q17 | What gene does the drug Phentermine Hydrochloride target? | The drug Phentermine Hydrochloride targets the gene SLC6A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%phentermine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%phentermine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%phentermine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5704', 'drugName': 'Phentermine Hydrochloride', 'tradeNames_string': 'Adipex-p, Fastin, Lomaira, Obestin-30, Oby-trim, Ona-mast, Phentermine hydrochloride, Suprenza, Tora, Wilpo', 'drugSynonyms_string': 'NSC-44090, Phentermine hcl, Phentermine hydrochloride, Phentermine hydrochloride civ, Zantryl', 'linkedDiseasesDrug_string': 'Obesity (EFO_0001073)', 'yearOfFirstApproval': 1973, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4353', 'drugName': 'Chlorphentermine Hydrochloride', 'tradeNames_string': 'Pre-sate', 'drugSynonyms_string': 'Chlorphentermine hcl, Chlorphentermine hydrochloride, NSC-76098, S-62, W 2426, W-2426', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.89 | Q17 | What gene does the drug Lenograstim target? | The drug Lenograstim targets the gene CSF3R. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lenograstim%" OR LOWER(tradeNames_string) LIKE "%lenograstim%" OR LOWER(drugSynonyms_string) LIKE "%lenograstim%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1088', 'drugName': 'Lenograstim', 'tradeNames_string': 'Granocyte-13, Granocyte-34', 'drugSynonyms_string': 'G-csf (cho cell derived), Glycosylated recombinant g-csf, Granocyte, Granulocyte colony-stimulating factor lenograstim, Lenograstim, Lenograstim (genetical recombination), Lenograstim rdna, Neutrogin, RG-CSF', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Prostate Cancer (MONDO_0008315), Neoplasm (EFO_0000616), Acute Myocardial Infarction (EFO_0008583), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CSF3R (ENSG00000119535)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1410 | Q17 | What gene does the drug Pergolide target? | The drug Pergolide targets 5 genes: DRD4, DRD1, DRD2, DRD5 and DRD3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pergolide%" OR LOWER(tradeNames_string) LIKE "%pergolide%" OR LOWER(drugSynonyms_string) LIKE "%pergolide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4078', 'drugName': 'Pergolide', 'tradeNames_string': '', 'drugSynonyms_string': 'Pergolide', 'linkedDiseasesDrug_string': 'Cocaine Dependence (EFO_0002610), Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 1988, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD5 (ENSG00000169676), DRD4 (ENSG00000069696), DRD1 (ENSG00000184845)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_6076', 'drugName': 'Pergolide Mesylate', 'tradeNames_string': 'Celance, Pergolide mesylate, Permax', 'drugSynonyms_string': 'LY 127809, LY-127809, NSC-319773, NSC-758442, Pergolide mesilate, Pergolide mesylate, Pergolide methanesulfonate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1988, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD5 (ENSG00000169676), DRD4 (ENSG00000069696), DRD1 (ENSG00000184845)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1900 | Q17 | What gene does the drug Guanadrel Sulfate target? | The drug Guanadrel Sulfate targets the gene SLC6A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%guanadrel sulfate%" OR LOWER(tradeNames_string) LIKE "%guanadrel sulfate%" OR LOWER(drugSynonyms_string) LIKE "%guanadrel sulfate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2355', 'drugName': 'Guanadrel Sulfate', 'tradeNames_string': 'Hylorel', 'drugSynonyms_string': 'CL-1388R, Guanadrel sulfate, Guanadrel sulphate, NSC-760062, U-28,288D, U-28288D', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.463 | Q17 | What gene does the drug Valbenazine target? | The drug Valbenazine targets the gene SLC18A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%valbenazine%" OR LOWER(tradeNames_string) LIKE "%valbenazine%" OR LOWER(drugSynonyms_string) LIKE "%valbenazine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4522', 'drugName': 'Valbenazine', 'tradeNames_string': '', 'drugSynonyms_string': 'Mt-5199, NBI-98854, Valbenazine', 'linkedDiseasesDrug_string': 'Tourette Syndrome (EFO_0004895), Huntington Disease (MONDO_0007739), Movement Disorder (EFO_0004280), Hair-Pulling (HP_0012167), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC18A2 (ENSG00000165646)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5423', 'drugName': 'Valbenazine Tosylate', 'tradeNames_string': 'Ingrezza', 'drugSynonyms_string': 'NBI-98854, Valbenazine ditosylate, Valbenazine tosilate, Valbenazine tosylate', 'linkedDiseasesDrug_string': 'Movement Disorder (EFO_0004280)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC18A2 (ENSG00000165646)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1830 | Q17 | What gene does the drug Gisadenafil target? | The drug Gisadenafil is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene PDE5A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gisadenafil%" OR LOWER(tradeNames_string) LIKE "%gisadenafil%" OR LOWER(drugSynonyms_string) LIKE "%gisadenafil%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1173', 'drugName': 'Gisadenafil', 'tradeNames_string': '', 'drugSynonyms_string': 'Gisadenafil, UK-369,003, UK-369003', 'linkedDiseasesDrug_string': 'Overactive Bladder (EFO_1000781), Benign Prostatic Hyperplasia (EFO_0000284), Chronic Obstructive Pulmonary Disease (EFO_0000341), Impotence (HP_0000802)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'PDE5A (ENSG00000138735)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.55 | Q17 | What gene does the drug Guanidine target? | The drug Guanidine targets 40 genes: KCNB1, KCND2, KCNA7, KCNG3, KCNA4, KCNQ1, KCNQ3, KCNA1, KCNC4, KCNS1, KCNG2, KCNA6, KCNV2, KCNA5, KCNH2, KCNS3, KCNQ4, KCND3, KCNG1, KCNB2, KCNH6, KCNC3, KCNG4, KCNF1, KCNH8, KCNS2, KCNA3, KCNQ2, KCNH4, KCNA10, KCNC2, KCNC1, KCNH1, KCNH3, KCNV1, KCNQ5, KCND1, KCNA2, KCNH7 and KCNH5. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%guanidine%" OR LOWER(tradeNames_string) LIKE "%guanidine%" OR LOWER(drugSynonyms_string) LIKE "%guanidine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5267', 'drugName': 'Iobenguane I 131', 'tradeNames_string': 'Azedra', 'drugSynonyms_string': '(131i)-mibg, 131 i-mibg, 131i-mibg, 3-iodobenzylguanidine (131i), 3-iodobenzylguanidine, i-131, I-131 metaiodobenzylguanidine, Iobenguane (131 i), Iobenguane (131i), Iobenguane i 131, Iobenguane i-131, Iobenguane, i-131, Iodine (131i) iobenguane, M131ibg, Metaiodobenzylguanidine i-131, Mibg i-131', 'linkedDiseasesDrug_string': 'Digestive System Neuroendocrine Neoplasm (MONDO_0024503), Neuroblastoma (EFO_0000621), Paraganglioma (EFO_1000453), Adrenal Gland Pheochromocytoma (EFO_0000239)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2190', 'drugName': 'Guanidine', 'tradeNames_string': '', 'drugSynonyms_string': 'Guanidine', 'linkedDiseasesDrug_string': 'Neuroendocrine Neoplasm (EFO_1001901), Small Cell Carcinoma (EFO_0008524), Muscle Weakness (HP_0001324), Myasthenia Gravis (EFO_0004991), Metastasis (EFO_0009708)', 'yearOfFirstApproval': 1939, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNQ1 (ENSG00000053918), KCND3 (ENSG00000171385), KCNH2 (ENSG00000055118), KCNA2 (ENSG00000177301), KCNA1 (ENSG00000111262), KCNQ2 (ENSG00000075043), KCNQ3 (ENSG00000184156), KCNA7 (ENSG00000104848), KCNQ5 (ENSG00000185760), KCNQ4 (ENSG00000117013), KCNH1 (ENSG00000143473), KCNA4 (ENSG00000182255), KCNA5 (ENSG00000130037), KCNA3 (ENSG00000177272), KCNA6 (ENSG00000151079), KCNC1 (ENSG00000129159), KCND2 (ENSG00000184408), KCNB2 (ENSG00000182674), KCNC4 (ENSG00000116396), KCNC3 (ENSG00000131398), KCNB1 (ENSG00000158445), KCNA10 (ENSG00000143105), KCNV1 (ENSG00000164794), KCNH5 (ENSG00000140015), KCNG3 (ENSG00000171126), KCNG4 (ENSG00000168418), KCNV2 (ENSG00000168263), KCNS1 (ENSG00000124134), KCNH8 (ENSG00000183960), KCNC2 (ENSG00000166006), KCNS3 (ENSG00000170745), KCNH6 (ENSG00000173826), KCNF1 (ENSG00000162975), KCNH7 (ENSG00000184611), KCND1 (ENSG00000102057), KCNG1 (ENSG00000026559), KCNG2 (ENSG00000178342), KCNH3 (ENSG00000135519), KCNS2 (ENSG00000156486), KCNH4 (ENSG00000089558)', 'numberLinkedTargets': 40}, {'UUID': 'DrugGeneTargets_v2_5118', 'drugName': 'Guanidine Hydrochloride', 'tradeNames_string': 'Guanidine hydrochloride', 'drugSynonyms_string': 'Guanidine HCl, Guanidine hydrochloride', 'linkedDiseasesDrug_string': 'Myasthenia Gravis (EFO_0004991), Small Cell Carcinoma (EFO_0008524), Muscle Weakness (HP_0001324)', 'yearOfFirstApproval': 1939, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNQ1 (ENSG00000053918), KCND3 (ENSG00000171385), KCNH2 (ENSG00000055118), KCNA2 (ENSG00000177301), KCNA1 (ENSG00000111262), KCNQ2 (ENSG00000075043), KCNQ3 (ENSG00000184156), KCNA7 (ENSG00000104848), KCNQ5 (ENSG00000185760), KCNQ4 (ENSG00000117013), KCNH1 (ENSG00000143473), KCNA4 (ENSG00000182255), KCNA5 (ENSG00000130037), KCNA3 (ENSG00000177272), KCNA6 (ENSG00000151079), KCNC1 (ENSG00000129159), KCND2 (ENSG00000184408), KCNB2 (ENSG00000182674), KCNC4 (ENSG00000116396), KCNC3 (ENSG00000131398), KCNB1 (ENSG00000158445), KCNA10 (ENSG00000143105), KCNV1 (ENSG00000164794), KCNH5 (ENSG00000140015), KCNG3 (ENSG00000171126), KCNG4 (ENSG00000168418), KCNV2 (ENSG00000168263), KCNS1 (ENSG00000124134), KCNH8 (ENSG00000183960), KCNC2 (ENSG00000166006), KCNS3 (ENSG00000170745), KCNH6 (ENSG00000173826), KCNF1 (ENSG00000162975), KCNH7 (ENSG00000184611), KCND1 (ENSG00000102057), KCNG1 (ENSG00000026559), KCNG2 (ENSG00000178342), KCNH3 (ENSG00000135519), KCNS2 (ENSG00000156486), KCNH4 (ENSG00000089558)', 'numberLinkedTargets': 40}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1503 | Q17 | What gene does the drug Int131 target? | The drug Int131 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene PPARG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%int131%" OR LOWER(tradeNames_string) LIKE "%int131%" OR LOWER(drugSynonyms_string) LIKE "%int131%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5994', 'drugName': 'Int131', 'tradeNames_string': '', 'drugSynonyms_string': 'AMG-131, CHS-131, INT-131, Ibrigampar, Int131, T-0903131, T0903131, T131', 'linkedDiseasesDrug_string': 'Type 2 Diabetes Mellitus (MONDO_0005148), Relapsing-Remitting Multiple Sclerosis (EFO_0003929)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'PPARG (ENSG00000132170)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.650 | Q17 | What gene does the drug Testosterone Undecanoate target? | The drug Testosterone Undecanoate targets the gene AR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%testosterone undecanoate%" OR LOWER(tradeNames_string) LIKE "%testosterone undecanoate%" OR LOWER(drugSynonyms_string) LIKE "%testosterone undecanoate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_939', 'drugName': 'Testosterone Undecanoate', 'tradeNames_string': 'Andriol, Aveed, Jatenzo, Kyzatrex, Nebido, Restandol, Restandol testocap, Tlando, Undestor', 'drugSynonyms_string': 'Kyzatrex, MK-3033, ORG 538, ORG-538, TSX-011, Testosterone 17.beta.-undecylate, Testosterone undecanoate, Testosterone undecylate, Testosterone, undecanoate (ester), Tlando', 'linkedDiseasesDrug_string': "Hypogonadism (MONDO_0002146), Coronary Artery Disease (EFO_0001645), Prostate Cancer (MONDO_0008315), Neoplasm (EFO_0000616), Respiratory Failure (EFO_0009686), Renal Cell Carcinoma (EFO_0000681), Klinefelter'S Syndrome (EFO_1001006), Hypogonadotropic Hypogonadism (MONDO_0018555), Aging (GO_0007568), Malnutrition (EFO_0008572), Sexual Dysfunction (EFO_0004714), Spinal Cord Injury (EFO_1001919), Orchitis (EFO_1001078)", 'yearOfFirstApproval': 2014, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.684 | Q17 | What gene does the drug Zilucoplan target? | The drug Zilucoplan is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene C5. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zilucoplan%" OR LOWER(tradeNames_string) LIKE "%zilucoplan%" OR LOWER(drugSynonyms_string) LIKE "%zilucoplan%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6204', 'drugName': 'Zilucoplan', 'tradeNames_string': '', 'drugSynonyms_string': 'RA101495, Zilucoplan', 'linkedDiseasesDrug_string': 'Myasthenia Gravis (EFO_0004991), Covid-19 (MONDO_0100096), Amyotrophic Lateral Sclerosis (MONDO_0004976)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'C5 (ENSG00000106804)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.224 | Q17 | What gene does the drug Ergotamine Tartrate target? | The drug Ergotamine Tartrate targets 7 genes: ADRA2A, HTR1D, ADRA2C, ADRA1A, ADRA1D, ADRA2B and ADRA1B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ergotamine tartrate%" OR LOWER(tradeNames_string) LIKE "%ergotamine tartrate%" OR LOWER(drugSynonyms_string) LIKE "%ergotamine tartrate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3552', 'drugName': 'Ergotamine', 'tradeNames_string': '', 'drugSynonyms_string': 'Ergotamine, Ergotamine Tartrate, NSC-95090', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277), Orthostatic Hypotension (EFO_0005252), Headache (HP_0002315)', 'yearOfFirstApproval': 1948, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1D (ENSG00000179546), ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 7}, {'UUID': 'DrugGeneTargets_v2_3551', 'drugName': 'Ergotamine', 'tradeNames_string': '', 'drugSynonyms_string': 'Ergotamine, Ergotamine Tartrate, NSC-95090', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277), Orthostatic Hypotension (EFO_0005252), Headache (HP_0002315)', 'yearOfFirstApproval': 1948, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1D (ENSG00000179546), ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 7}, {'UUID': 'DrugGeneTargets_v2_3132', 'drugName': 'Ergotamine Tartrate', 'tradeNames_string': 'Cafergot, Ergomar, Ergostat, Femergin, Gynergen, Lingraine, Medihaler ergotamine, Migril, Wigrettes', 'drugSynonyms_string': 'Ergotamine bitartrate, Ergotamine d-tartrate, Ergotamine tartrate, Ergotamini tartras, Gotamine tartrate, NSC-41869', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277), Headache (HP_0002315)', 'yearOfFirstApproval': 1948, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), HTR1D (ENSG00000179546)', 'numberLinkedTargets': 7}, {'UUID': 'DrugGeneTargets_v2_3131', 'drugName': 'Ergotamine Tartrate', 'tradeNames_string': 'Cafergot, Ergomar, Ergostat, Femergin, Gynergen, Lingraine, Medihaler ergotamine, Migril, Wigrettes', 'drugSynonyms_string': 'Ergotamine bitartrate, Ergotamine d-tartrate, Ergotamine tartrate, Ergotamini tartras, Gotamine tartrate, NSC-41869', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277), Headache (HP_0002315)', 'yearOfFirstApproval': 1948, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), HTR1D (ENSG00000179546)', 'numberLinkedTargets': 7}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.116 | Q17 | What gene does the drug Fluorometholone target? | The drug Fluorometholone targets the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fluorometholone%" OR LOWER(tradeNames_string) LIKE "%fluorometholone%" OR LOWER(drugSynonyms_string) LIKE "%fluorometholone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4240', 'drugName': 'Fluorometholone', 'tradeNames_string': 'Fluaton, Fluor-op, Fml forte, Fml fte, Fml-neo, Oxylone', 'drugSynonyms_string': 'Fluorometholone, NSC-33001', 'linkedDiseasesDrug_string': 'Corneal Opacity (HP_0007957), Hemorrhoid (EFO_0009552), Eye Inflammation (EFO_0005752), Dry Eye Syndrome (EFO_1000906), Inflammation (MP_0001845), Acne (EFO_0003894)', 'yearOfFirstApproval': 1972, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_873', 'drugName': 'Fluorometholone Acetate', 'tradeNames_string': 'Flarex', 'drugSynonyms_string': 'Fluorometholone 17-acetate, Fluorometholone acetate, NSC-47438, U-17,323, U-17323', 'linkedDiseasesDrug_string': 'Hemorrhoid (EFO_0009552), Eye Inflammation (EFO_0005752), Acne (EFO_0003894)', 'yearOfFirstApproval': 1986, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1552 | Q17 | What gene does the drug Oxycodone Hydrochloride target? | The drug Oxycodone Hydrochloride targets the gene OPRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%oxycodone hydrochloride%" OR LOWER(tradeNames_string) LIKE "%oxycodone hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%oxycodone hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4049', 'drugName': 'Oxycodone Hydrochloride', 'tradeNames_string': 'Abtard, Candox, Carexil, Dolocodon pr, Leveraxo, Longtec, Lynlor, Oxaydo, Oxecta, Oxeltra, Oxycodone hydrochloride, Oxycontin, Oxylan, Oxynorm, Reltebon, Roxicodone, Roxybond, Shortec, Zomestine', 'drugSynonyms_string': 'Anhydrous oxycodone hydrochloride, Endocodone, Oxecta, Oxycodone hcl, Oxycodone hydrochloride, Oxycodone hydrochloride cii', 'linkedDiseasesDrug_string': 'Osteoarthritis, Hip (EFO_1000786), Pain (EFO_0003843), Chronic Pain (HP_0012532), Osteoarthritis, Knee (EFO_0004616), Low Back Pain (HP_0003419)', 'yearOfFirstApproval': 1950, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3599', 'drugName': 'Oxymorphone', 'tradeNames_string': '', 'drugSynonyms_string': '14-hydroxydihydromorphinone, 7,8-dihydro-14-hydroxymorphinone, Dihydroxymorphinone, IDS-NO-003, NIH 10323, NSC-19045, Numorphan, Opana, Oxycodone hydrochloride impurity, oxymorphone-, Oxymorphone, Oxymorphone cii', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843), Chronic Pain (HP_0012532), Injury (EFO_0000546), Head And Neck Malignant Neoplasia (EFO_0006859)', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1303 | Q17 | What gene does the drug Tripelennamine Citrate target? | The drug Tripelennamine Citrate targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tripelennamine citrate%" OR LOWER(tradeNames_string) LIKE "%tripelennamine citrate%" OR LOWER(drugSynonyms_string) LIKE "%tripelennamine citrate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_703', 'drugName': 'Tripelennamine Citrate', 'tradeNames_string': '', 'drugSynonyms_string': 'NSC-757360, Tripelennamine citrate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1948, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.987 | Q17 | What gene does the drug Teriparatide Acetate target? | The drug Teriparatide Acetate targets the gene PTH1R. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%teriparatide acetate%" OR LOWER(tradeNames_string) LIKE "%teriparatide acetate%" OR LOWER(drugSynonyms_string) LIKE "%teriparatide acetate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3571', 'drugName': 'Teriparatide Acetate', 'tradeNames_string': 'Parathar', 'drugSynonyms_string': 'Ak-159, Ak159, HPTH 1-34, HPTH 1-34 (ACETATE SALT), HPTH-1-34, Teriparatide acetate, Teriparatide acetate hydrate', 'linkedDiseasesDrug_string': 'Osteoporosis (EFO_0003882), 22Q11.2 Deletion Syndrome (MONDO_0018923), Postmenopausal Osteoporosis (EFO_0003854), Hypoparathyroidism (EFO_0009451), Psoriasis Vulgaris (EFO_1001494)', 'yearOfFirstApproval': 1987, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTH1R (ENSG00000160801)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.177 | Q17 | What gene does the drug Insulin Zinc Susp Prompt Purified Pork target? | The drug Insulin Zinc Susp Prompt Purified Pork targets the gene INSR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%insulin zinc susp prompt purified pork%" OR LOWER(tradeNames_string) LIKE "%insulin zinc susp prompt purified pork%" OR LOWER(drugSynonyms_string) LIKE "%insulin zinc susp prompt purified pork%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1271', 'drugName': 'Insulin Zinc Susp Prompt Purified Pork', 'tradeNames_string': 'Semilente', 'drugSynonyms_string': 'Insulin zinc susp prompt purified pork', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1650 | Q17 | What gene does the drug Milrinone Lactate target? | The drug Milrinone Lactate targets the gene PDE3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%milrinone lactate%" OR LOWER(tradeNames_string) LIKE "%milrinone lactate%" OR LOWER(drugSynonyms_string) LIKE "%milrinone lactate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3912', 'drugName': 'Milrinone Lactate', 'tradeNames_string': 'Milrinone lactate, Primacor', 'drugSynonyms_string': 'Milrinone lactate', 'linkedDiseasesDrug_string': 'Heart Failure (EFO_0003144), Ventricular Arrhythmia (HP_0004308)', 'yearOfFirstApproval': 1987, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE3A (ENSG00000172572)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.596 | Q17 | What gene does the drug Difenoxin target? | The drug Difenoxin targets the gene OPRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%difenoxin%" OR LOWER(tradeNames_string) LIKE "%difenoxin%" OR LOWER(drugSynonyms_string) LIKE "%difenoxin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_614', 'drugName': 'Difenoxin', 'tradeNames_string': '', 'drugSynonyms_string': 'Acscn-9168, Difenoxin, Diphenoxylate related compound a, Diphenoxylic acid, IDS-ND-007, Lyspafen, MCN-JR-15,403-11, Mcn-jr 15403-11, R 15,403 [AS HYDROCHLORIDE], R-15403', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1978, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3761', 'drugName': 'Difenoxin Hydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'Difenoxin hcl, Difenoxin hydrochloride, Difenoxine hydrochloride, R 15,403, R-15403', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1978, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1560 | Q17 | What gene does the drug Levosalbutamol target? | The drug Levosalbutamol targets the gene ADRB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%levosalbutamol%" OR LOWER(tradeNames_string) LIKE "%levosalbutamol%" OR LOWER(drugSynonyms_string) LIKE "%levosalbutamol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3721', 'drugName': 'Levosalbutamol', 'tradeNames_string': '', 'drugSynonyms_string': 'ASF-1096, Albuterol (r)-form, Levalbuterol, Levosalbutamol, R-salbutamol, Xopenex', 'linkedDiseasesDrug_string': 'Chronic Obstructive Pulmonary Disease (EFO_0000341), Bronchospasm (HP_0025428), Asthma (MONDO_0004979)', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2058', 'drugName': 'Levalbuterol Tartrate', 'tradeNames_string': 'Xopenex, Xopenex hfa', 'drugSynonyms_string': 'Levalbuterol tartrate, Levosalbutamol tartrate', 'linkedDiseasesDrug_string': 'Bronchospasm (HP_0025428), Asthma (MONDO_0004979)', 'yearOfFirstApproval': 2005, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1198', 'drugName': 'Levalbuterol Hydrochloride', 'tradeNames_string': 'Levalbuterol hydrochloride, Xopenex', 'drugSynonyms_string': 'Albuterol (r)-form hydrochloride, Albuterol hydrochloride, r-, Levalbuterol hcl, Levalbuterol hydrochloride, Levosalbutamol hydrochloride, NSC-759255', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979)', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.19 | Q17 | What gene does the drug Bms-690514 target? | The drug Bms-690514 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 6 genes: FLT4, ERBB4, FLT1, ERBB2, KDR and EGFR | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bms-690514%" OR LOWER(tradeNames_string) LIKE "%bms-690514%" OR LOWER(drugSynonyms_string) LIKE "%bms-690514%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2007', 'drugName': 'Bms-690514', 'tradeNames_string': '', 'drugSynonyms_string': 'Bms 6690514, Bms 690514, Bms-690514', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Non-Small Cell Lung Carcinoma (EFO_0003060), Breast Cancer (MONDO_0007254)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'EGFR (ENSG00000146648), ERBB2 (ENSG00000141736), ERBB4 (ENSG00000178568), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_2006', 'drugName': 'Bms-690514', 'tradeNames_string': '', 'drugSynonyms_string': 'Bms 6690514, Bms 690514, Bms-690514', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Non-Small Cell Lung Carcinoma (EFO_0003060), Breast Cancer (MONDO_0007254)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'EGFR (ENSG00000146648), ERBB2 (ENSG00000141736), ERBB4 (ENSG00000178568), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_2009', 'drugName': 'Bms-690514', 'tradeNames_string': '', 'drugSynonyms_string': 'Bms 6690514, Bms 690514, Bms-690514', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Non-Small Cell Lung Carcinoma (EFO_0003060), Breast Cancer (MONDO_0007254)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'EGFR (ENSG00000146648), ERBB2 (ENSG00000141736), ERBB4 (ENSG00000178568), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_2008', 'drugName': 'Bms-690514', 'tradeNames_string': '', 'drugSynonyms_string': 'Bms 6690514, Bms 690514, Bms-690514', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Non-Small Cell Lung Carcinoma (EFO_0003060), Breast Cancer (MONDO_0007254)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'EGFR (ENSG00000146648), ERBB2 (ENSG00000141736), ERBB4 (ENSG00000178568), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052)', 'numberLinkedTargets': 6}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.429 | Q17 | What gene does the drug Abiraterone target? | The drug Abiraterone targets 5 genes: SRD5A2, SRD5A3, SRD5A1, AR and CYP17A1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%abiraterone%" OR LOWER(tradeNames_string) LIKE "%abiraterone%" OR LOWER(drugSynonyms_string) LIKE "%abiraterone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6320', 'drugName': 'Abiraterone', 'tradeNames_string': 'Zytiga', 'drugSynonyms_string': 'Abiraterone, CB 7598, CB-7598, NSC-741232', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Prostate Cancer (MONDO_0008315), Neoplasm (EFO_0000616), Metastatic Prostate Cancer (EFO_0000196), Prostate Carcinoma (EFO_0001663), Prostate Adenocarcinoma (EFO_0000673)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083), CYP17A1 (ENSG00000148795), SRD5A1 (ENSG00000145545), SRD5A2 (ENSG00000277893), SRD5A3 (ENSG00000128039)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_2354', 'drugName': 'Abiraterone Acetate', 'tradeNames_string': 'Yonsa, Zytiga', 'drugSynonyms_string': 'Abiraterone acetate, CB-7630, CB7630, NSC-748121, NSC-749227', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Salivary Gland Neoplasm (EFO_0003826), Liver Disease (EFO_0001421), Non-Small Cell Lung Carcinoma (EFO_0003060), Congenital Adrenal Hyperplasia (MONDO_0018479), Metastatic Prostate Cancer (EFO_0000196), Renal Insufficiency (HP_0000083), Prostate Carcinoma (EFO_0001663), Prostate Adenocarcinoma (EFO_0000673), Classic Congenital Adrenal Hyperplasia Due To 21-Hydroxylase Deficiency (MONDO_0008728)', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CYP17A1 (ENSG00000148795)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_6322', 'drugName': 'Abiraterone', 'tradeNames_string': 'Zytiga', 'drugSynonyms_string': 'Abiraterone, CB 7598, CB-7598, NSC-741232', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Prostate Cancer (MONDO_0008315), Neoplasm (EFO_0000616), Metastatic Prostate Cancer (EFO_0000196), Prostate Carcinoma (EFO_0001663), Prostate Adenocarcinoma (EFO_0000673)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083), CYP17A1 (ENSG00000148795), SRD5A1 (ENSG00000145545), SRD5A2 (ENSG00000277893), SRD5A3 (ENSG00000128039)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_6321', 'drugName': 'Abiraterone', 'tradeNames_string': 'Zytiga', 'drugSynonyms_string': 'Abiraterone, CB 7598, CB-7598, NSC-741232', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Prostate Cancer (MONDO_0008315), Neoplasm (EFO_0000616), Metastatic Prostate Cancer (EFO_0000196), Prostate Carcinoma (EFO_0001663), Prostate Adenocarcinoma (EFO_0000673)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083), CYP17A1 (ENSG00000148795), SRD5A1 (ENSG00000145545), SRD5A2 (ENSG00000277893), SRD5A3 (ENSG00000128039)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1345 | Q17 | What gene does the drug Onabotulinumtoxina target? | The drug Onabotulinumtoxina targets the gene SNAP25. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%onabotulinumtoxina%" OR LOWER(tradeNames_string) LIKE "%onabotulinumtoxina%" OR LOWER(drugSynonyms_string) LIKE "%onabotulinumtoxina%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2163', 'drugName': 'Onabotulinumtoxina', 'tradeNames_string': 'Botox, Botox cosmetic, Botox/botox cosmetic', 'drugSynonyms_string': 'Bontoxilysin, Botulin, Botulinum neurotoxin, Botulinum toxin, Botulinum toxin type a purified neurotoxin complex, Onabotulinumtoxina, Onaclostox, RTI-150, RTI150', 'linkedDiseasesDrug_string': 'Fecal Incontinence (EFO_0009523), Androgenetic Alopecia (EFO_0004191), Nervous System Disease (EFO_0000618), Migraine Disorder (MONDO_0005277), Esotropia (HP_0000565), Scleroderma (EFO_1001993), Spinal Cord Injury (EFO_1001919), Graves Ophthalmopathy (EFO_1001466), Neuroma (EFO_0009619), Burning Mouth Syndrome (EFO_1000850), Neuropathic Pain (EFO_0005762), Plantar Fasciitis (EFO_1001909), Tension-Type Headache (HP_0012228), Nasal Cavity Polyp (EFO_1000391), Atrial Flutter (EFO_0003911), Abnormality Of Connective Tissue (HP_0003549), Benign Prostatic Hyperplasia (EFO_0000284), Contracture (EFO_0003899), Interstitial Cystitis (EFO_0008507), Prostatitis (EFO_0003830), Myofascial Pain Syndrome (EFO_1001054), Erectile Dysfunction (EFO_0004234), Tendinopathy (EFO_1001434), Multiple Sclerosis (MONDO_0005301), Pain (EFO_0003843), Obesity (EFO_0001073), Aging (GO_0007568), Tremor (HP_0001337), Skin Aging (EFO_0005422), Headache (HP_0002315), Patellofemoral Pain Syndrome (EFO_1001092), Dementia (HP_0000726), Morbid Obesity (EFO_0001074), Restless Legs Syndrome (EFO_0004270), Hyperreflexia (HP_0001347), Ventricular Tachycardia (EFO_0005306), Benign Essential Blepharospasm (Orphanet_93955), Stroke (EFO_0000712), Severe Cutaneous Adverse Reaction (EFO_0006346), Granuloma (HP_0032252), Gingival Overgrowth (MONDO_0002507), Epicondylitis (EFO_1001887), Rectum Cancer (EFO_1000657), Sleep Apnea (EFO_0003877), Hemiplegia (EFO_0009453), Osteoarthritis (MONDO_0005178), Low Back Pain (HP_0003419), Neuralgia (EFO_0009430), Carpal Tunnel Syndrome (EFO_0004143), Spasticity (HP_0001257), Shoulder Pain (HP_0030834), Esophageal Carcinoma (EFO_0002916), Psoriasis Vulgaris (EFO_1001494), Atrial Fibrillation (EFO_0000275), Rotator Cuff Tear (EFO_1001250), Bursitis (MONDO_0002471), Osteoarthritis, Knee (EFO_0004616), Epiphora (HP_0009926), Cardiac Arrhythmia (EFO_0004269), Acne (EFO_0003894), Ulcer Disease (MONDO_0043839), Keloid (EFO_0004212), Pancreatic Carcinoma (EFO_0002618), Atrophic Rhinitis (EFO_0007159), Vocal Cord Paralysis (HP_0001605), Compartment Syndrome (MONDO_0004001), Brain Injury (MONDO_0043510), Depressive Disorder (MONDO_0002050), Trigeminal Neuralgia (EFO_1001219), Urgency Urinary Incontinence (EFO_0006865), Facial Pain (EFO_0009625), Strabismus (HP_0000486), Postherpetic Neuralgia (MONDO_0041052), Essential Tremor (EFO_0003108), Chronic Pain (HP_0012532), Raynaud Disease (EFO_1001145), Torticollis (HP_0000473), Major Depressive Disorder (MONDO_0002009), Stomach Neoplasm (EFO_0003897), Lateral Epicondylitis (EFO_1001896), Cerebral Palsy (EFO_1000632), Anal Fissure (HP_0012390), Overactive Bladder (EFO_1000781), Headache Disorder (EFO_0009550), Dry Eye Syndrome (EFO_1000906), Injury (EFO_0000546), Muscle Cramp (EFO_0009846), Neurogenic Bladder (HP_0000011), Gastroparesis (EFO_1000948), Muscular Disease (EFO_0002970), Drooling (HP_0002307), Parkinson Disease (MONDO_0005180), Scoliosis (EFO_0004273), Pruritus (HP_0000989), Rhinitis (EFO_0008521), Urinary Retention (HP_0000016), Joint Disease (EFO_1000999), Urinary Incontinence (HP_0000020), Thoracic Outlet Syndrome (EFO_0007507), Hyperhidrosis (HP_0000975), Abnormality Of The Skin (HP_0000951)', 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SNAP25 (ENSG00000132639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.289 | Q17 | What gene does the drug Hydroxychloroquine Sulfate target? | The drug Hydroxychloroquine Sulfate targets 2 genes: TLR9 and TLR7. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%hydroxychloroquine sulfate%" OR LOWER(tradeNames_string) LIKE "%hydroxychloroquine sulfate%" OR LOWER(drugSynonyms_string) LIKE "%hydroxychloroquine sulfate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3878', 'drugName': 'Hydroxychloroquine Sulfate', 'tradeNames_string': 'Ercoquin, Hydroxychloroquine sulfate, Oxichlorochine, Plaquenil, Quensyl, Quinoric', 'drugSynonyms_string': 'Ercoquin, Hydroxychloroquine Sulfate, Hydroxychloroquine sulfate, Hydroxychloroquine sulphate, NSC-4375, Oxichlorochine sulfate, Oxiklorin, Quensyl, TCMDC-123987', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Cholangiocarcinoma (EFO_0005221), Rheumatic Disease (EFO_0005755), Covid-19 (MONDO_0100096), Cutaneous Melanoma (EFO_0000389), Systemic Lupus Erythematosus (MONDO_0007915), Interstitial Lung Disease (EFO_0004244), Rheumatoid Arthritis (EFO_0000685), Lung Disease (EFO_0003818), Antiphospholipid Syndrome (EFO_0002689), Cutaneous Lupus Erythematosus (EFO_0003834), Coronavirus Infectious Disease (EFO_0007224), Malaria (EFO_0001068), X-Linked Alport Syndrome (MONDO_0010520)', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TLR9 (ENSG00000239732), TLR7 (ENSG00000196664)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3879', 'drugName': 'Hydroxychloroquine Sulfate', 'tradeNames_string': 'Ercoquin, Hydroxychloroquine sulfate, Oxichlorochine, Plaquenil, Quensyl, Quinoric', 'drugSynonyms_string': 'Ercoquin, Hydroxychloroquine Sulfate, Hydroxychloroquine sulfate, Hydroxychloroquine sulphate, NSC-4375, Oxichlorochine sulfate, Oxiklorin, Quensyl, TCMDC-123987', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Cholangiocarcinoma (EFO_0005221), Rheumatic Disease (EFO_0005755), Covid-19 (MONDO_0100096), Cutaneous Melanoma (EFO_0000389), Systemic Lupus Erythematosus (MONDO_0007915), Interstitial Lung Disease (EFO_0004244), Rheumatoid Arthritis (EFO_0000685), Lung Disease (EFO_0003818), Antiphospholipid Syndrome (EFO_0002689), Cutaneous Lupus Erythematosus (EFO_0003834), Coronavirus Infectious Disease (EFO_0007224), Malaria (EFO_0001068), X-Linked Alport Syndrome (MONDO_0010520)', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TLR9 (ENSG00000239732), TLR7 (ENSG00000196664)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1584 | Q17 | What gene does the drug Dyphylline target? | The drug Dyphylline targets 5 genes: PDE4D, PDE3A, PDE4B, PDE4A and PDE4C. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dyphylline%" OR LOWER(tradeNames_string) LIKE "%dyphylline%" OR LOWER(drugSynonyms_string) LIKE "%dyphylline%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2641', 'drugName': 'Dyphylline', 'tradeNames_string': 'Dilor, Dilor-400, Lufyllin, Neothylline', 'drugSynonyms_string': 'Diprophylline, Dyphilline, Dyphylline, Glyphylline, NSC-14305', 'linkedDiseasesDrug_string': 'Airway Obstruction (HP_0006536)', 'yearOfFirstApproval': 1951, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650), PDE3A (ENSG00000172572)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_2642', 'drugName': 'Dyphylline', 'tradeNames_string': 'Dilor, Dilor-400, Lufyllin, Neothylline', 'drugSynonyms_string': 'Diprophylline, Dyphilline, Dyphylline, Glyphylline, NSC-14305', 'linkedDiseasesDrug_string': 'Airway Obstruction (HP_0006536)', 'yearOfFirstApproval': 1951, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650), PDE3A (ENSG00000172572)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.434 | Q17 | What gene does the drug Glutethimide target? | The drug Glutethimide targets 16 genes: GABRG2, GABRE, GABRA4, GABRQ, GABRD, GABRA3, GABRP, GABRA5, GABRG3, GABRB2, GABRB3, GABRG1, GABRA2, GABRB1, GABRA6 and GABRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%glutethimide%" OR LOWER(tradeNames_string) LIKE "%glutethimide%" OR LOWER(drugSynonyms_string) LIKE "%glutethimide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2691', 'drugName': 'Aminoglutethimide', 'tradeNames_string': 'Cytadren, Orimeten', 'drugSynonyms_string': 'Aminoglutethimide, Cytadren, NSC-330915', 'linkedDiseasesDrug_string': 'Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CYP19A1 (ENSG00000137869), CYP11A1 (ENSG00000140459)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2692', 'drugName': 'Aminoglutethimide', 'tradeNames_string': 'Cytadren, Orimeten', 'drugSynonyms_string': 'Aminoglutethimide, Cytadren, NSC-330915', 'linkedDiseasesDrug_string': 'Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CYP19A1 (ENSG00000137869), CYP11A1 (ENSG00000140459)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3020', 'drugName': 'Glutethimide', 'tradeNames_string': 'Doriden, Glutethimide', 'drugSynonyms_string': 'Elrodorm, Glutethimide, NSC-95239, Noxyron, Rigenox, Sarodormin', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1976, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1640 | Q17 | What gene does the drug Lenzilumab target? | The drug Lenzilumab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CSF2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lenzilumab%" OR LOWER(tradeNames_string) LIKE "%lenzilumab%" OR LOWER(drugSynonyms_string) LIKE "%lenzilumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3438', 'drugName': 'Lenzilumab', 'tradeNames_string': '', 'drugSynonyms_string': 'KB-003, KB003, Lenzilumab', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Pneumonia (EFO_0003106), Neoplasm Of Mature B-Cells (EFO_0000096), Covid-19 (MONDO_0100096), Chronic Myelomonocytic Leukemia (EFO_1001779), Rheumatoid Arthritis (EFO_0000685)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'CSF2 (ENSG00000164400)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1245 | Q17 | What gene does the drug Baclofen target? | The drug Baclofen targets 2 genes: GABBR2 and GABBR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%baclofen%" OR LOWER(tradeNames_string) LIKE "%baclofen%" OR LOWER(drugSynonyms_string) LIKE "%baclofen%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3627', 'drugName': 'Baclofen', 'tradeNames_string': 'Baclofen, Baclospas-10, Fleqsuvy, Gablofen, Kemstro, Lioresal, Lioresal intrath, Lyflex, Lyvispah, Ozobax', 'drugSynonyms_string': '(rs)-baclofen, BA-34,647, BA-34647, Baclofen, Fleqsuvy, Lyvispah, NSC-755906', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Cerebral Palsy (EFO_1000632), Spinal Cord Disease (EFO_0009488), Multiple Sclerosis (MONDO_0005301), Pain (EFO_0003843), Obesity (EFO_0001073), Spasticity (HP_0001257), Cannabis Dependence (EFO_0007191), Reproductive System Disease (EFO_0000512), Spinal Cord Injury (EFO_1001919), Charcot-Marie-Tooth Disease (MONDO_0015626), Hepatocellular Carcinoma (EFO_0000182), Nicotine Dependence (EFO_0003768), Fragile X Syndrome (MONDO_0010383), Cocaine Dependence (EFO_0002610), Alcohol Withdrawal (EFO_0004777), Drug Dependence (EFO_0003890), Rigidity (HP_0002063), Brain Injury (MONDO_0043510), Ataxia Telangiectasia (MONDO_0008840), Gastroesophageal Reflux Disease (EFO_0003948), Alcohol Dependence (MONDO_0007079), Alcoholic Liver Cirrhosis (EFO_1000802)', 'yearOfFirstApproval': 1977, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABBR1 (ENSG00000204681), GABBR2 (ENSG00000136928)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_336', 'drugName': 'Arbaclofen', 'tradeNames_string': '', 'drugSynonyms_string': '(r)-baclofen, Arbaclofen, Baclofen (r)-form, Baclofen, (r)-, Baclofen, r(-)-, Baclofen, r-, D-baclofen, R-(-)-baclofen, STX-209, STX209', 'linkedDiseasesDrug_string': 'Autism Spectrum Disorder (EFO_0003756), Fragile X Syndrome (MONDO_0010383), Spasticity (HP_0001257)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'GABBR1 (ENSG00000204681), GABBR2 (ENSG00000136928)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3516', 'drugName': 'Arbaclofen Placarbil', 'tradeNames_string': '', 'drugSynonyms_string': 'Arbaclofen placarbil, XP-19986, XP19986', 'linkedDiseasesDrug_string': 'Multiple Sclerosis (MONDO_0005301), Gastroesophageal Reflux Disease (EFO_0003948), Back Pain (HP_0003418), Spasticity (HP_0001257), Alcohol Dependence (MONDO_0007079)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'GABBR1 (ENSG00000204681), GABBR2 (ENSG00000136928)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.676 | Q17 | What gene does the drug Levocabastine Hydrochloride target? | The drug Levocabastine Hydrochloride targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%levocabastine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%levocabastine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%levocabastine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_674', 'drugName': 'Levocabastine Hydrochloride', 'tradeNames_string': 'Livostin', 'drugSynonyms_string': 'Levocabastine hcl, Levocabastine hydrochloride, R 50,547, R-50547', 'linkedDiseasesDrug_string': 'Rhinitis, Allergic, Perennial (EFO_1001417)', 'yearOfFirstApproval': 1993, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.32 | Q17 | What gene does the drug Pheniramine Maleate target? | The drug Pheniramine Maleate targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pheniramine maleate%" OR LOWER(tradeNames_string) LIKE "%pheniramine maleate%" OR LOWER(drugSynonyms_string) LIKE "%pheniramine maleate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_463', 'drugName': 'Pheniramine Maleate', 'tradeNames_string': 'Avil ret, Daneral-sa', 'drugSynonyms_string': 'Antolozine, Daneral, Fervex, Inhiston, NSC-757270, Naphcon a, PM-241, Pheniramine Maleate, Pheniramine hydrogen maleate, Pheniramine maleate, Prophenpyridamine maleate, Trimeton, Trimetose', 'linkedDiseasesDrug_string': 'Respiratory Tract Infectious Disorder (MONDO_0024355), Common Cold (EFO_0007214), Influenza (EFO_0007328)', 'yearOfFirstApproval': 1994, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_221', 'drugName': 'Chlorpheniramine Maleate', 'tradeNames_string': 'Allercalm allergy relief, Allerief, Alunex, Antagonate, Calimal, Chlor-trimeton, Chlorphenamine, Chlorpheniramine maleate, Efidac 24 chlorpheniramine maleate, Hayleve, Kloromin, Phenetron, Piriject, Piriton, Piriton allergy, Pyridamal 100, Rhino-syrup allergy, Rimarin, Teldrin', 'drugSynonyms_string': '(+)-Chlorpheniramine Maleate, Chlorphenamine hydrogen maleate, Chlorphenamine maleate, Chlorphenamini hydrogenomaleas, Chlorpheniramine Maleate, Chlorpheniramine maleate, Chlorprophenpyridamine maleate, Efidac, Histaspan, NSC-756684, Neorestamin, Pyridamal, Synistamin', 'linkedDiseasesDrug_string': 'Sinusitis (EFO_0007486), Seasonal Allergic Rhinitis (EFO_0003956), Cough (HP_0012735), Allergic Rhinitis (EFO_0005854), Sunburn (EFO_0003958)', 'yearOfFirstApproval': 1950, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1014', 'drugName': 'Brompheniramine Maleate', 'tradeNames_string': 'Brompheniramine maleate, Dimegan, Dimetane, Dimetane-ten, Dimotane, Dimotane l.a.', 'drugSynonyms_string': '(+)-Brompheniramine Maleate, Brompheniramine fumarate, Brompheniramine maleate, NSC-758652, Parabromdylamine maleate', 'linkedDiseasesDrug_string': 'Allergic Disease (MONDO_0005271), Cough (HP_0012735), Common Cold (EFO_0007214)', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_431', 'drugName': 'Dexbrompheniramine Maleate', 'tradeNames_string': 'Disomer', 'drugSynonyms_string': 'Brompheniramine d-form maleate, Dexbrompheniramine fumarate, Dexbrompheniramine maleate', 'linkedDiseasesDrug_string': 'Seasonal Allergic Rhinitis (EFO_0003956)', 'yearOfFirstApproval': 1963, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_6213', 'drugName': 'Dexchlorpheniramine Maleate', 'tradeNames_string': 'Dexchlorpheniramine maleate, Mylaramine, Polaramine', 'drugSynonyms_string': 'Chlorpheniramine d-form maleate, Chlorpheniramine maleate, (s)-, D-chlorpheniramine maleate, Dexchlorpheniramine maleate, NSC-759156', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Multiple Sclerosis (MONDO_0005301), Rhinitis, Allergic, Perennial (EFO_1001417), Seasonal Allergic Rhinitis (EFO_0003956), Angioedema (EFO_0005532), Vasomotor Rhinitis (EFO_0007533), Allergic Rhinitis (EFO_0005854), Allergic Disease (MONDO_0005271), Urticaria (EFO_0005531), Sunburn (EFO_0003958)', 'yearOfFirstApproval': 1981, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.934 | Q17 | What gene does the drug Abt-560 target? | The drug Abt-560 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: CHRNA4 and CHRNB2 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%abt-560%" OR LOWER(tradeNames_string) LIKE "%abt-560%" OR LOWER(drugSynonyms_string) LIKE "%abt-560%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6065', 'drugName': 'Abt-560', 'tradeNames_string': '', 'drugSynonyms_string': 'Abt-560', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': -1, 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNB2 (ENSG00000160716), CHRNA4 (ENSG00000101204)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.982 | Q17 | What gene does the drug Treprostinil Diolamine target? | The drug Treprostinil Diolamine targets the gene PTGIR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%treprostinil diolamine%" OR LOWER(tradeNames_string) LIKE "%treprostinil diolamine%" OR LOWER(drugSynonyms_string) LIKE "%treprostinil diolamine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2433', 'drugName': 'Treprostinil Diolamine', 'tradeNames_string': 'Orenitram, Ut-15c', 'drugSynonyms_string': 'Treprostinil diethanolamine, Treprostinil diolamin, Treprostinil diolamine, UT-15C', 'linkedDiseasesDrug_string': 'Systemic Scleroderma (EFO_0000717), Pulmonary Arterial Hypertension (EFO_0001361)', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGIR (ENSG00000160013)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.217 | Q17 | What gene does the drug Acetophenazine target? | The drug Acetophenazine targets the gene DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%acetophenazine%" OR LOWER(tradeNames_string) LIKE "%acetophenazine%" OR LOWER(drugSynonyms_string) LIKE "%acetophenazine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4266', 'drugName': 'Acetophenazine', 'tradeNames_string': '', 'drugSynonyms_string': 'Acetophenazine, Tindal', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407)', 'yearOfFirstApproval': 1961, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3064', 'drugName': 'Acetophenazine Maleate', 'tradeNames_string': 'Tindal', 'drugSynonyms_string': 'Acephenazine dimaleate, Acetophenazine dimaleate, Acetophenazine maleate, NSC-169180, NSC-70600, SCH 6673, SCH-6673', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1961, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1130 | Q17 | What gene does the drug Galantamine target? | The drug Galantamine targets the gene ACHE. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%galantamine%" OR LOWER(tradeNames_string) LIKE "%galantamine%" OR LOWER(drugSynonyms_string) LIKE "%galantamine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1632', 'drugName': 'Galantamine Hydrobromide', 'tradeNames_string': 'Galantamine hydrobromide, Razadyne, Razadyne er', 'drugSynonyms_string': '(-)-galantamine hydrobromide, Galantamine hydrobromide, Galanthamine hydrobromide, Jilkon hydrobromide, Lycoremine hydrobromide, Nivalin, Nivaline, Tamilin', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Frontotemporal Dementia (MONDO_0017276), Cognitive Impairment (HP_0100543), Mental Or Behavioural Disorder (EFO_0000677), Dementia (HP_0000726), Schizophrenia (MONDO_0005090), Vascular Dementia (EFO_0004718)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACHE (ENSG00000087085)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3143', 'drugName': 'Galantamine', 'tradeNames_string': 'Acumor xl, Consion xl, Elmino xl, Galsya xl, Galzemic xl, Gatalin xl, Gazylan xl, Lotprosin xl, Luventa xl, Reminyl, Reminyl xl, Zeebral xl', 'drugSynonyms_string': '(-)-galantamine, (-)-galanthamine, Galantamine, Galanthamine, NSC-100058, Razadyne', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Alzheimer Disease (MONDO_0004975), Orthostatic Hypotension (EFO_0005252), Obesity (EFO_0001073), Vascular Dementia (EFO_0004718), Nicotine Dependence (EFO_0003768), Dementia (HP_0000726), Schizoaffective Disorder (EFO_0005411), Anxiety (EFO_0005230), Fish-Eye Disease (Orphanet_79292), Cocaine Dependence (EFO_0002610), Memory Impairment (EFO_0001072), Mental Or Behavioural Disorder (EFO_0000677), Subarachnoid Hemorrhage (EFO_0000713), Lewy Body Dementia (EFO_0006792), Depressive Disorder (MONDO_0002050), Hiv Infection (EFO_0000764), Frontotemporal Dementia (MONDO_0017276), Cognitive Impairment (HP_0100543), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACHE (ENSG00000087085)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.330 | Q17 | What gene does the drug Insulin Zinc Susp Extended Purified Beef target? | The drug Insulin Zinc Susp Extended Purified Beef targets the gene INSR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%insulin zinc susp extended purified beef%" OR LOWER(tradeNames_string) LIKE "%insulin zinc susp extended purified beef%" OR LOWER(drugSynonyms_string) LIKE "%insulin zinc susp extended purified beef%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_994', 'drugName': 'Insulin Zinc Susp Extended Purified Beef', 'tradeNames_string': 'Ultralente', 'drugSynonyms_string': 'Insulin zinc susp extended purified beef', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.566 | Q17 | What gene does the drug Benzphetamine target? | The drug Benzphetamine targets 2 genes: SLC6A2 and SLC18A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%benzphetamine%" OR LOWER(tradeNames_string) LIKE "%benzphetamine%" OR LOWER(drugSynonyms_string) LIKE "%benzphetamine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_168', 'drugName': 'Benzphetamine Hydrochloride', 'tradeNames_string': 'Benzphetamine hydrochloride, Didrex', 'drugSynonyms_string': 'Benzfetamine hydrochloride, Benzphetamine chloride, Benzphetamine hcl, Benzphetamine hydrochloride, Benzphetamine hydrochloride ciii, NSC-10937, U-0441', 'linkedDiseasesDrug_string': 'Obesity (EFO_0001073)', 'yearOfFirstApproval': 1960, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC18A2 (ENSG00000165646)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_167', 'drugName': 'Benzphetamine Hydrochloride', 'tradeNames_string': 'Benzphetamine hydrochloride, Didrex', 'drugSynonyms_string': 'Benzfetamine hydrochloride, Benzphetamine chloride, Benzphetamine hcl, Benzphetamine hydrochloride, Benzphetamine hydrochloride ciii, NSC-10937, U-0441', 'linkedDiseasesDrug_string': 'Obesity (EFO_0001073)', 'yearOfFirstApproval': 1960, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC18A2 (ENSG00000165646)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3490', 'drugName': 'Benzphetamine', 'tradeNames_string': '', 'drugSynonyms_string': 'Benzfetamine', 'linkedDiseasesDrug_string': 'Obesity (EFO_0001073)', 'yearOfFirstApproval': 1960, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC18A2 (ENSG00000165646)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3489', 'drugName': 'Benzphetamine', 'tradeNames_string': '', 'drugSynonyms_string': 'Benzfetamine', 'linkedDiseasesDrug_string': 'Obesity (EFO_0001073)', 'yearOfFirstApproval': 1960, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC18A2 (ENSG00000165646)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1112 | Q17 | What gene does the drug Dexibuprofen target? | The drug Dexibuprofen targets 2 genes: PTGS2 and PTGS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dexibuprofen%" OR LOWER(tradeNames_string) LIKE "%dexibuprofen%" OR LOWER(drugSynonyms_string) LIKE "%dexibuprofen%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1446', 'drugName': 'Dexibuprofen', 'tradeNames_string': 'Seractil', 'drugSynonyms_string': '(s)-ibuprofen, Dexibuprofen, IBU-TAB, NSC-759814, Neoprofen, Rufen, S-ibuprofen', 'linkedDiseasesDrug_string': 'Rheumatic Disease (EFO_0005755), Fever (HP_0001945), Pain (EFO_0003843)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.707 | Q17 | What gene does the drug Protirelin target? | The drug Protirelin targets the gene TRHR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%protirelin%" OR LOWER(tradeNames_string) LIKE "%protirelin%" OR LOWER(drugSynonyms_string) LIKE "%protirelin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4776', 'drugName': 'Protirelin', 'tradeNames_string': 'Thypinone, Thyrel trh, Trh-cambridge', 'drugSynonyms_string': '5-oxo-pro-his-pro-nh2, A-38579, ABBOTT-38579, Lopremone, NSC-760113, Protirelin, Protirelin tartrate, Protirelin, synthetic, Relefact trh, SYNTHETIC TRH, Synthetic TRH, Thyroid releasing hormone, Thyroliberin, Thyrotropin releasing hormone, Thyrotropin-releasing factor, Thyrotropin-releasing hormone', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Acute Respiratory Distress Syndrome (EFO_1000637)', 'yearOfFirstApproval': 1976, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TRHR (ENSG00000174417)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1979 | Q17 | What gene does the drug Mephenytoin target? | The drug Mephenytoin targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mephenytoin%" OR LOWER(tradeNames_string) LIKE "%mephenytoin%" OR LOWER(drugSynonyms_string) LIKE "%mephenytoin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5011', 'drugName': 'Mephenytoin', 'tradeNames_string': 'Mesantoin', 'drugSynonyms_string': 'Mephenytoin, Methoin, NSC-34652', 'linkedDiseasesDrug_string': 'Epilepsy (EFO_0000474)', 'yearOfFirstApproval': 1946, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1189 | Q17 | What gene does the drug Atn-161 target? | The drug Atn-161 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 4 genes: ITGB1, ITGA5, ITGB3 and ITGAV | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%atn-161%" OR LOWER(tradeNames_string) LIKE "%atn-161%" OR LOWER(drugSynonyms_string) LIKE "%atn-161%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_173', 'drugName': 'Atn-161', 'tradeNames_string': '', 'drugSynonyms_string': 'ATN 161, ATN-161, Ac-phscn-nh2, Atn-161', 'linkedDiseasesDrug_string': 'Central Nervous System Neoplasm (EFO_1000158), Renal Cell Carcinoma (EFO_0000681)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'ITGB1 (ENSG00000150093), ITGA5 (ENSG00000161638), ITGB3 (ENSG00000259207), ITGAV (ENSG00000138448)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_174', 'drugName': 'Atn-161', 'tradeNames_string': '', 'drugSynonyms_string': 'ATN 161, ATN-161, Ac-phscn-nh2, Atn-161', 'linkedDiseasesDrug_string': 'Central Nervous System Neoplasm (EFO_1000158), Renal Cell Carcinoma (EFO_0000681)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'ITGB1 (ENSG00000150093), ITGA5 (ENSG00000161638), ITGB3 (ENSG00000259207), ITGAV (ENSG00000138448)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.345 | Q17 | What gene does the drug Clobazam target? | The drug Clobazam targets 16 genes: GABRG2, GABRE, GABRA4, GABRQ, GABRD, GABRA3, GABRP, GABRA5, GABRG3, GABRB2, GABRB3, GABRG1, GABRA2, GABRB1, GABRA6 and GABRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%clobazam%" OR LOWER(tradeNames_string) LIKE "%clobazam%" OR LOWER(drugSynonyms_string) LIKE "%clobazam%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5981', 'drugName': 'Clobazam', 'tradeNames_string': 'Frisium, Onfi, Perizam, Sympazan, Tapclob, Urbanyl', 'drugSynonyms_string': 'Clobazam, Colbazam, H 4723, H-4723, HR 376, HR-376, LM 2717, LM-2717, Mystan, NSC-336279, Urbadan', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843), Dravet Syndrome (Orphanet_33069), Lennox-Gastaut Syndrome (MONDO_0016532), Dementia (HP_0000726), Neuropathic Pain (EFO_0005762), Anxiety (EFO_0005230), Epilepsy (EFO_0000474), Depressive Disorder (MONDO_0002050), Seizure (HP_0001250), Low Back Pain (HP_0003419), Schizophrenia (MONDO_0005090), Epilepsia Partialis Continua (EFO_1000924)', 'yearOfFirstApproval': 2005, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.636 | Q17 | What gene does the drug Epinephrine target? | The drug Epinephrine targets 9 genes: ADRA2A, ADRB1, ADRA2C, ADRA1A, ADRA1D, ADRA1B, ADRB3, ADRA2B and ADRB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%epinephrine%" OR LOWER(tradeNames_string) LIKE "%epinephrine%" OR LOWER(drugSynonyms_string) LIKE "%epinephrine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1884', 'drugName': 'Epinephrine Bitartrate', 'tradeNames_string': 'Bronitin, Bronitin mist, Medihaler-epi', 'drugSynonyms_string': '(-)-Epinephrine Bitartrate, Adrenalin tartrate, Adrenaline (as tartrate), Adrenaline acid tartrate, Adrenaline bitartate, Adrenaline bitartrate, Epinephrine bitartrate, Epinephrine d-bitartrate, Epinephrine hydrogen tartrate, Epinephrine tartrate, Epinephrini hydrogenotartras, L-epinephrine hydrogen tartrate, NSC-756755', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843)', 'yearOfFirstApproval': 1965, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), ADRB3 (ENSG00000188778)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_1992', 'drugName': 'Norepinephrine', 'tradeNames_string': '', 'drugSynonyms_string': '(-)-noradrenaline, Levarterenol, Levophed, NSC-757246, Nor adrenalin, Norepinephrine, R-norepinephrine', 'linkedDiseasesDrug_string': 'Orthostatic Hypotension (EFO_0005252), Obesity (EFO_0001073), Hypotension (EFO_0005251), Ischemic Stroke (HP_0002140), Acute Lung Injury (EFO_0004610), Septic Shock (EFO_0006834), Radiodermatitis (MONDO_0043771), Cardiovascular Disease (EFO_0000319), Renal Insufficiency (HP_0000083), Sepsis (HP_0100806), Shock (HP_0031273), Inflammation (MP_0001845), Brain Injury (MONDO_0043510), Depressive Disorder (MONDO_0002050), Congenital Heart Disease (EFO_0005207), Acute Hypotension (EFO_0002497), Heart Disease (EFO_0003777), Cognitive Impairment (HP_0100543), Poliomyelitis (EFO_0007450)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), ADRB3 (ENSG00000188778)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_1843', 'drugName': 'Norepinephrine Bitartrate', 'tradeNames_string': 'Adrenor, Aktamin, Levarterenol Bitartrate, Levophed, Noradrenaline, Norepinephrine bitartrate, Norepinephrine bitartrate in 5% dextrose', 'drugSynonyms_string': 'Aktamin, Arterenol, tartrate, monohydrate, Binodrenal, Levarterenol bitartrate, NSC-169106, Noradrenaline, Noradrenaline (as tartrate), Noradrenaline bitartrate, Noradrenaline tartrate, Norepinephrine, Norepinephrine bitartrate, Norepinephrine bitartrate monohydrate, Norepinephrine d-bitartrate, Norepinephrine hydrochloride', 'linkedDiseasesDrug_string': 'Acute Hypotension (EFO_0002497), Sepsis (HP_0100806), Acute Lung Injury (EFO_0004610), Ischemic Stroke (HP_0002140), Poliomyelitis (EFO_0007450), Cardiovascular Disease (EFO_0000319), Renal Insufficiency (HP_0000083), Hypotension (EFO_0005251)', 'yearOfFirstApproval': 1950, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), ADRB3 (ENSG00000188778)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_842', 'drugName': 'Dipivefrin', 'tradeNames_string': '', 'drugSynonyms_string': 'DPE, Dipivalyl epinephrine, Dipivefrin, Dipivefrine', 'linkedDiseasesDrug_string': 'Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), ADRB3 (ENSG00000188778)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_901', 'drugName': 'Epinephrine', 'tradeNames_string': 'Adren co, Adrenaclick, Adrenalin, Ana-Kit, Ana-guard, Anapen, Anaphylactic shock drug kit, Asma-vydrin, Asthmahaler, Auvi-q, Bronkaid mist, Brovon, Emerade, Epi e z pen jr, Epinephrine, Epinephrine (copackaged), Epipen, Epipen e z pen, Epipen jr, Epipen jr., Eppy, Gppe inh soln, Jext, Medihaler-epi, Primatene, Primatene mist, Riddobron, Riddofan, Rybarvin, Simplene, Soln made to rybarvin for, Sus-Phrine, Sus-Phrine Sulfite-Free, Sus-phrine sulfite free, Symjepi, Twinject 0.15, Twinject 0.3', 'drugSynonyms_string': '(-)-(r)-epinephrine, (-)-epinephrine, Adrenaline, Adrenalinum, Epinephrine, Epinephrine hcl, Epinephrine hydrochloride, Epinephrinum, Glauposine, L-epinephrine hydrochloride, Levo-methylaminoethanolcatechol, NSC-62786, Nephridine, Racepinefrine hydrochloride, (r)-, Racepinefrine, (r)-, Sus-phrine sulphite-free, Susphrine, Tonogen, Twinject', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Infection (EFO_0000544), Hemorrhage (MP_0001914), Benign Muscle Neoplasm (MONDO_0003061), Pain (EFO_0003843), Male Reproductive Organ Cancer (EFO_0007355), Injury (EFO_0000546), Appendicitis (EFO_0007149), Hypotension (EFO_0005251), Allergic Rhinitis (EFO_0005854), Musculoskeletal System Disease (EFO_0009676), Glaucoma (MONDO_0005041), Gastric Cancer (MONDO_0001056), Muscle Cramp (EFO_0009846), Bronchiolitis (HP_0011950), Parathyroid Adenoma (EFO_1001087), Urticaria (EFO_0005531), Hypospadias (EFO_0004209), Anaphylaxis (MONDO_0100053), Breast Cancer (MONDO_0007254), Acute Lung Injury (EFO_0004610), Rotator Cuff Tear (EFO_1001250), Septic Shock (EFO_0006834), Seasonal Allergic Rhinitis (EFO_0003956), Ventricular Fibrillation (EFO_0004287), Cardiovascular Disease (EFO_0000319), Osteoarthritis, Knee (EFO_0004616), Angioedema (EFO_0005532), Sudden Cardiac Arrest (EFO_0004278), Mydriasis (HP_0011499), Cardiac Arrest (EFO_0009492), Asthma (MONDO_0004979), Ventricular Tachycardia (EFO_0005306), Sinusitis (EFO_0007486), Rhinitis, Allergic, Perennial (EFO_1001417), Tachypnea (EFO_0009840), Shock (HP_0031273), Airway Obstruction (HP_0006536), Depressive Disorder (MONDO_0002050), Nasal Congestion (HP_0001742), Skin Neoplasm (EFO_0004198), Hemoptysis (HP_0002105), Allergic Disease (MONDO_0005271), Osteoarthritis (MONDO_0005178), Pulpitis (EFO_1001139), Cognitive Impairment (HP_0100543), Non-Small Cell Lung Carcinoma (EFO_0003060), Gastrointestinal Hemorrhage (HP_0002239), Chronic Pain (HP_0012532), Heart Failure (EFO_0003144), Type Iii Hypersensitivity Reaction Disease (EFO_1001222)', 'yearOfFirstApproval': 1976, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), ADRB3 (ENSG00000188778)', 'numberLinkedTargets': 9}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.150 | Q17 | What gene does the drug Mivacurium Chloride target? | The drug Mivacurium Chloride targets 5 genes: CHRNB1, CHRNA1, CHRND, CHRNE and CHRNG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mivacurium chloride%" OR LOWER(tradeNames_string) LIKE "%mivacurium chloride%" OR LOWER(drugSynonyms_string) LIKE "%mivacurium chloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3976', 'drugName': 'Mivacurium Chloride', 'tradeNames_string': 'Mivacron, Mivacurium chloride', 'drugSynonyms_string': 'BW B109OU DICHLORIDE, BW-1090U DICHLORIDE, BW-B109OU, BW-B109OU DICHLORIDE, BWB109OU, Mivacurium chloride, mivacurium', 'linkedDiseasesDrug_string': 'Decreased Liver Function (HP_0001410)', 'yearOfFirstApproval': 1992, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1197 | Q17 | What gene does the drug Sorafenib Tosylate target? | The drug Sorafenib Tosylate targets 9 genes: BRAF, FLT3, FLT4, RET, KIT, RAF1, FLT1, KDR and PDGFRB. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sorafenib tosylate%" OR LOWER(tradeNames_string) LIKE "%sorafenib tosylate%" OR LOWER(drugSynonyms_string) LIKE "%sorafenib tosylate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1548', 'drugName': 'Sorafenib Tosylate', 'tradeNames_string': 'Nexavar', 'drugSynonyms_string': 'BAY 54-9085, BAY-54-9085, Sorafenib tosilate, Sorafenib tosylate', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Chronic Lymphocytic Leukemia (EFO_0000095), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Rectal Carcinoma (MONDO_0044937), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Myeloid Sarcoma (EFO_1001052), Acute Promyelocytic Leukemia (EFO_0000224), Mantle Cell Lymphoma (EFO_1001469), Breast Cancer (MONDO_0007254), Prostate Cancer (MONDO_0008315), Papillary Renal Cell Carcinoma (EFO_0000640), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Chromophobe Renal Cell Carcinoma (EFO_0000335), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Anaplastic Oligodendroglioma (EFO_0002501), Tongue Neoplasm (EFO_0003871), Hypopharyngeal Carcinoma (EFO_0002938), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Thyroid Cancer (MONDO_0002108), Renal Cell Carcinoma (EFO_0000681), Brain Neoplasm (EFO_0003833), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Liver Cancer (MONDO_0002691), Rectum Cancer (EFO_1000657), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Colorectal Adenocarcinoma (EFO_0000365), Uterine Carcinosarcoma (EFO_1000613), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Follicular Thyroid Carcinoma (EFO_0000501), Desmoid-Type Fibromatosis (EFO_0009907)', 'yearOfFirstApproval': 2005, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_1546', 'drugName': 'Sorafenib Tosylate', 'tradeNames_string': 'Nexavar', 'drugSynonyms_string': 'BAY 54-9085, BAY-54-9085, Sorafenib tosilate, Sorafenib tosylate', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Chronic Lymphocytic Leukemia (EFO_0000095), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Rectal Carcinoma (MONDO_0044937), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Myeloid Sarcoma (EFO_1001052), Acute Promyelocytic Leukemia (EFO_0000224), Mantle Cell Lymphoma (EFO_1001469), Breast Cancer (MONDO_0007254), Prostate Cancer (MONDO_0008315), Papillary Renal Cell Carcinoma (EFO_0000640), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Chromophobe Renal Cell Carcinoma (EFO_0000335), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Anaplastic Oligodendroglioma (EFO_0002501), Tongue Neoplasm (EFO_0003871), Hypopharyngeal Carcinoma (EFO_0002938), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Thyroid Cancer (MONDO_0002108), Renal Cell Carcinoma (EFO_0000681), Brain Neoplasm (EFO_0003833), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Liver Cancer (MONDO_0002691), Rectum Cancer (EFO_1000657), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Colorectal Adenocarcinoma (EFO_0000365), Uterine Carcinosarcoma (EFO_1000613), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Follicular Thyroid Carcinoma (EFO_0000501), Desmoid-Type Fibromatosis (EFO_0009907)', 'yearOfFirstApproval': 2005, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_1544', 'drugName': 'Sorafenib Tosylate', 'tradeNames_string': 'Nexavar', 'drugSynonyms_string': 'BAY 54-9085, BAY-54-9085, Sorafenib tosilate, Sorafenib tosylate', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Chronic Lymphocytic Leukemia (EFO_0000095), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Rectal Carcinoma (MONDO_0044937), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Myeloid Sarcoma (EFO_1001052), Acute Promyelocytic Leukemia (EFO_0000224), Mantle Cell Lymphoma (EFO_1001469), Breast Cancer (MONDO_0007254), Prostate Cancer (MONDO_0008315), Papillary Renal Cell Carcinoma (EFO_0000640), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Chromophobe Renal Cell Carcinoma (EFO_0000335), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Anaplastic Oligodendroglioma (EFO_0002501), Tongue Neoplasm (EFO_0003871), Hypopharyngeal Carcinoma (EFO_0002938), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Thyroid Cancer (MONDO_0002108), Renal Cell Carcinoma (EFO_0000681), Brain Neoplasm (EFO_0003833), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Liver Cancer (MONDO_0002691), Rectum Cancer (EFO_1000657), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Colorectal Adenocarcinoma (EFO_0000365), Uterine Carcinosarcoma (EFO_1000613), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Follicular Thyroid Carcinoma (EFO_0000501), Desmoid-Type Fibromatosis (EFO_0009907)', 'yearOfFirstApproval': 2005, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_1543', 'drugName': 'Sorafenib Tosylate', 'tradeNames_string': 'Nexavar', 'drugSynonyms_string': 'BAY 54-9085, BAY-54-9085, Sorafenib tosilate, Sorafenib tosylate', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Chronic Lymphocytic Leukemia (EFO_0000095), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Rectal Carcinoma (MONDO_0044937), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Myeloid Sarcoma (EFO_1001052), Acute Promyelocytic Leukemia (EFO_0000224), Mantle Cell Lymphoma (EFO_1001469), Breast Cancer (MONDO_0007254), Prostate Cancer (MONDO_0008315), Papillary Renal Cell Carcinoma (EFO_0000640), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Chromophobe Renal Cell Carcinoma (EFO_0000335), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Anaplastic Oligodendroglioma (EFO_0002501), Tongue Neoplasm (EFO_0003871), Hypopharyngeal Carcinoma (EFO_0002938), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Thyroid Cancer (MONDO_0002108), Renal Cell Carcinoma (EFO_0000681), Brain Neoplasm (EFO_0003833), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Liver Cancer (MONDO_0002691), Rectum Cancer (EFO_1000657), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Colorectal Adenocarcinoma (EFO_0000365), Uterine Carcinosarcoma (EFO_1000613), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Follicular Thyroid Carcinoma (EFO_0000501), Desmoid-Type Fibromatosis (EFO_0009907)', 'yearOfFirstApproval': 2005, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_1549', 'drugName': 'Sorafenib Tosylate', 'tradeNames_string': 'Nexavar', 'drugSynonyms_string': 'BAY 54-9085, BAY-54-9085, Sorafenib tosilate, Sorafenib tosylate', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Chronic Lymphocytic Leukemia (EFO_0000095), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Rectal Carcinoma (MONDO_0044937), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Myeloid Sarcoma (EFO_1001052), Acute Promyelocytic Leukemia (EFO_0000224), Mantle Cell Lymphoma (EFO_1001469), Breast Cancer (MONDO_0007254), Prostate Cancer (MONDO_0008315), Papillary Renal Cell Carcinoma (EFO_0000640), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Chromophobe Renal Cell Carcinoma (EFO_0000335), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Anaplastic Oligodendroglioma (EFO_0002501), Tongue Neoplasm (EFO_0003871), Hypopharyngeal Carcinoma (EFO_0002938), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Thyroid Cancer (MONDO_0002108), Renal Cell Carcinoma (EFO_0000681), Brain Neoplasm (EFO_0003833), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Liver Cancer (MONDO_0002691), Rectum Cancer (EFO_1000657), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Colorectal Adenocarcinoma (EFO_0000365), Uterine Carcinosarcoma (EFO_1000613), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Follicular Thyroid Carcinoma (EFO_0000501), Desmoid-Type Fibromatosis (EFO_0009907)', 'yearOfFirstApproval': 2005, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_1547', 'drugName': 'Sorafenib Tosylate', 'tradeNames_string': 'Nexavar', 'drugSynonyms_string': 'BAY 54-9085, BAY-54-9085, Sorafenib tosilate, Sorafenib tosylate', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Chronic Lymphocytic Leukemia (EFO_0000095), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Rectal Carcinoma (MONDO_0044937), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Myeloid Sarcoma (EFO_1001052), Acute Promyelocytic Leukemia (EFO_0000224), Mantle Cell Lymphoma (EFO_1001469), Breast Cancer (MONDO_0007254), Prostate Cancer (MONDO_0008315), Papillary Renal Cell Carcinoma (EFO_0000640), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Chromophobe Renal Cell Carcinoma (EFO_0000335), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Anaplastic Oligodendroglioma (EFO_0002501), Tongue Neoplasm (EFO_0003871), Hypopharyngeal Carcinoma (EFO_0002938), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Thyroid Cancer (MONDO_0002108), Renal Cell Carcinoma (EFO_0000681), Brain Neoplasm (EFO_0003833), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Liver Cancer (MONDO_0002691), Rectum Cancer (EFO_1000657), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Colorectal Adenocarcinoma (EFO_0000365), Uterine Carcinosarcoma (EFO_1000613), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Follicular Thyroid Carcinoma (EFO_0000501), Desmoid-Type Fibromatosis (EFO_0009907)', 'yearOfFirstApproval': 2005, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_1545', 'drugName': 'Sorafenib Tosylate', 'tradeNames_string': 'Nexavar', 'drugSynonyms_string': 'BAY 54-9085, BAY-54-9085, Sorafenib tosilate, Sorafenib tosylate', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Chronic Lymphocytic Leukemia (EFO_0000095), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Rectal Carcinoma (MONDO_0044937), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Myeloid Sarcoma (EFO_1001052), Acute Promyelocytic Leukemia (EFO_0000224), Mantle Cell Lymphoma (EFO_1001469), Breast Cancer (MONDO_0007254), Prostate Cancer (MONDO_0008315), Papillary Renal Cell Carcinoma (EFO_0000640), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Chromophobe Renal Cell Carcinoma (EFO_0000335), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Anaplastic Oligodendroglioma (EFO_0002501), Tongue Neoplasm (EFO_0003871), Hypopharyngeal Carcinoma (EFO_0002938), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Thyroid Cancer (MONDO_0002108), Renal Cell Carcinoma (EFO_0000681), Brain Neoplasm (EFO_0003833), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Liver Cancer (MONDO_0002691), Rectum Cancer (EFO_1000657), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Colorectal Adenocarcinoma (EFO_0000365), Uterine Carcinosarcoma (EFO_1000613), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Follicular Thyroid Carcinoma (EFO_0000501), Desmoid-Type Fibromatosis (EFO_0009907)', 'yearOfFirstApproval': 2005, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'numberLinkedTargets': 9}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.365 | Q17 | What gene does the drug Umeclidinium Bromide target? | The drug Umeclidinium Bromide targets the gene CHRM3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%umeclidinium bromide%" OR LOWER(tradeNames_string) LIKE "%umeclidinium bromide%" OR LOWER(drugSynonyms_string) LIKE "%umeclidinium bromide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5459', 'drugName': 'Umeclidinium Bromide', 'tradeNames_string': 'Incruse ellipta', 'drugSynonyms_string': 'Anoro ellipta, GSK-573719A, GSK573719A, Umeclidinium brom, Umeclidinium bromide', 'linkedDiseasesDrug_string': 'Chronic Bronchitis (EFO_0006505), Asthma (MONDO_0004979), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Emphysema (EFO_0000464)', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.86 | Q17 | What gene does the drug Echothiophate target? | The drug Echothiophate targets the gene ACHE. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%echothiophate%" OR LOWER(tradeNames_string) LIKE "%echothiophate%" OR LOWER(drugSynonyms_string) LIKE "%echothiophate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2260', 'drugName': 'Echothiophate', 'tradeNames_string': '', 'drugSynonyms_string': 'Echothiophate, Echothiophate cation, Echothiophate ion, Ecothiopate, Ecothiopate cation', 'linkedDiseasesDrug_string': 'Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 1960, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACHE (ENSG00000087085)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2129', 'drugName': 'Echothiophate Iodide', 'tradeNames_string': 'Phospholine iodide', 'drugSynonyms_string': '217-MI, Echodide, Echothiophate iodide, Ecostigmine iodide, Ecothiopate iodide', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1960, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACHE (ENSG00000087085)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.49 | Q17 | What gene does the drug Leuprolide Acetate target? | The drug Leuprolide Acetate targets the gene GNRHR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%leuprolide acetate%" OR LOWER(tradeNames_string) LIKE "%leuprolide acetate%" OR LOWER(drugSynonyms_string) LIKE "%leuprolide acetate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4802', 'drugName': 'Leuprolide Acetate', 'tradeNames_string': 'Carcinil, Eligard, Eligard kit, Fensolvi kit, Leuprolide acetate, Leuprorelin, Lupron, Lupron Depot Ped, Lupron depot, Lupron depot-ped, Lupron depot-ped kit, Lutrate depot kit, Viadur', 'drugSynonyms_string': 'A-43818, ABBOTT-43818, Carcinil, Enantone, Fensolvi, Leuplin, Leuporelin acetate, Leuprolide acetate, Leuprolide monoacetate, Leuprorelin acetate, Lucrin, Lupaneta, Lutrate depot, Prostap, TAP-144, Tap-144-sr, Trenantone', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Alzheimer Disease (MONDO_0004975), Male Infertility (EFO_0004248), Uterine Fibroid (EFO_0000731), Obesity (EFO_0001073), Prostate Carcinoma (EFO_0001663), Prostate Adenocarcinoma (EFO_0000673), Breast Neoplasm (EFO_0003869), Central Precocious Puberty (EFO_0009029), Prostate Cancer (MONDO_0008315), Mantle Cell Lymphoma (EFO_1001469), Breast Cancer (MONDO_0007254), Postpartum Depression (EFO_0007453), Hypertension (EFO_0000537), Endometriosis (EFO_0001065), Precocious Puberty (MONDO_0000088), Hodgkins Lymphoma (EFO_0000183), Cognitive Impairment (HP_0100543), Metastatic Prostate Cancer (EFO_0000196), Bulimia Nervosa (EFO_0005204)', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GNRHR (ENSG00000109163)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.474 | Q17 | What gene does the drug Mitapivat target? | The drug Mitapivat targets the gene PKLR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mitapivat%" OR LOWER(tradeNames_string) LIKE "%mitapivat%" OR LOWER(drugSynonyms_string) LIKE "%mitapivat%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4932', 'drugName': 'Mitapivat', 'tradeNames_string': '', 'drugSynonyms_string': 'AG-348, Ag-348, Mitapivat, Pkr-in-1', 'linkedDiseasesDrug_string': 'Familial Hemolytic Anemia (MONDO_0003689), Beta-Thalassemia (Orphanet_848), Thalassemia (EFO_1001996), Anemia (Phenotype) (EFO_0004272), Sickle Cell Anemia (MONDO_0011382), Alpha-Thalassemia (Orphanet_846)', 'yearOfFirstApproval': 2022, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PKLR (ENSG00000143627)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2811', 'drugName': 'Mitapivat Sulfate', 'tradeNames_string': 'Pyrukynd', 'drugSynonyms_string': 'AG-348 HEMISULFATE SESQUIHYDRATE, AG-348 sulfate hydrate, Mitapivat sulfate, Pyrukynd', 'linkedDiseasesDrug_string': 'Familial Hemolytic Anemia (MONDO_0003689)', 'yearOfFirstApproval': 2022, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PKLR (ENSG00000143627)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.158 | Q17 | What gene does the drug Sergliflozin Etabonate target? | The drug Sergliflozin Etabonate is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene SLC5A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sergliflozin etabonate%" OR LOWER(tradeNames_string) LIKE "%sergliflozin etabonate%" OR LOWER(drugSynonyms_string) LIKE "%sergliflozin etabonate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2686', 'drugName': 'Sergliflozin Etabonate', 'tradeNames_string': '', 'drugSynonyms_string': 'GW-869682X, GW-869683X, GW869682X, Sergliflozin, Sergliflozin a, Sergliflozin etabonate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': -1, 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC5A2 (ENSG00000140675)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.764 | Q17 | What gene does the drug Fluvastatin target? | The drug Fluvastatin targets the gene HMGCR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fluvastatin%" OR LOWER(tradeNames_string) LIKE "%fluvastatin%" OR LOWER(drugSynonyms_string) LIKE "%fluvastatin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1307', 'drugName': 'Fluvastatin', 'tradeNames_string': '', 'drugSynonyms_string': 'Fluvas, Fluvastatin, NSC-758896', 'linkedDiseasesDrug_string': 'Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Aortic Stenosis (EFO_0000266), Familial Hypercholesterolemia (EFO_0004911), Cardiovascular Disease (EFO_0000319), Hypercholesterolemia (HP_0003124), Melanoma (EFO_0000756), Chronic Hepatitis C Virus Infection (EFO_0004220), Glioma (EFO_0005543), Disorder Of Lipid Metabolism (Orphanet_309005), Antiphospholipid Syndrome (EFO_0002689), Alport Syndrome (MONDO_0018965), Hepatitis C Virus Infection (EFO_0003047), Impotence (HP_0000802)', 'yearOfFirstApproval': 1993, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HMGCR (ENSG00000113161)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1184', 'drugName': 'Fluvastatin Sodium', 'tradeNames_string': 'Dorisin xl, Fluvastatin sodium, Lescol, Lescol xl, Luvinsta xl, Nandovar xl, Pinmactil, Stefluvin xl', 'drugSynonyms_string': 'Almastatin, Canef, Cranoc, Fluindostatin, Fluvastatin sodium, Fluvastatin sodium salt, Fractal, Lipaxan, Lochol, Locol, Primexin, Vastin, XU 62-320, XU-62-320', 'linkedDiseasesDrug_string': 'Familial Hypercholesterolemia (EFO_0004911), Breast Cancer (MONDO_0007254), Hypercholesterolemia (HP_0003124)', 'yearOfFirstApproval': 1993, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HMGCR (ENSG00000113161)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1027 | Q17 | What gene does the drug Voretigene Neparvovec target? | The drug Voretigene Neparvovec is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene RPE65. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%voretigene neparvovec%" OR LOWER(tradeNames_string) LIKE "%voretigene neparvovec%" OR LOWER(drugSynonyms_string) LIKE "%voretigene neparvovec%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1065', 'drugName': 'Voretigene Neparvovec', 'tradeNames_string': '', 'drugSynonyms_string': 'AAV-2-HRPE65V2, AAV2-hRPE65v2, Luxturna, SPK-RPE65, Voretigene neparvovec, Voretigene neparvovec rzyl, Voretigene neparvovec-rzyl', 'linkedDiseasesDrug_string': 'Leber Congenital Amaurosis (MONDO_0018998), Eye Disease (EFO_0003966)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'RPE65 (ENSG00000116745)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1200 | Q17 | What gene does the drug Lofexidine Hydrochloride target? | The drug Lofexidine Hydrochloride targets 3 genes: ADRA2A, ADRA2C and ADRA2B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lofexidine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%lofexidine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%lofexidine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3056', 'drugName': 'Lofexidine Hydrochloride', 'tradeNames_string': 'Britlofex, Lofexidine, Lucemyra', 'drugSynonyms_string': 'Lofexidine hcl, Lofexidine hydrochloride, MDL 14,042, MDL-14042, NSC-759654', 'linkedDiseasesDrug_string': 'Substance Withdrawal Syndrome (EFO_0005800), Opioid Dependence (EFO_0005611)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1404 | Q17 | What gene does the drug Mexiletine target? | The drug Mexiletine targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mexiletine%" OR LOWER(tradeNames_string) LIKE "%mexiletine%" OR LOWER(drugSynonyms_string) LIKE "%mexiletine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_485', 'drugName': 'Mexiletine', 'tradeNames_string': '', 'drugSynonyms_string': '(rs)-mexiletine, Dl-mexiletine, Mexiletine', 'linkedDiseasesDrug_string': 'Charcot-Marie-Tooth Disease (MONDO_0015626), Benign Essential Blepharospasm (Orphanet_93955), Ventricular Fibrillation (EFO_0004287), Chronic Pain (HP_0012532), Peripheral Nervous System Disease (EFO_0009387), Myocardial Infarction (EFO_0000612), Sudden Cardiac Arrest (EFO_0004278), Cardiac Arrhythmia (EFO_0004269), Dystonic Disorder (MONDO_0003441), Ventricular Arrhythmia (HP_0004308), Steinert Myotonic Dystrophy (Orphanet_273), Irritable Bowel Syndrome (EFO_0000555), Myotonic Dystrophy (MONDO_0016107)', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_4048', 'drugName': 'Mexiletine Hydrochloride', 'tradeNames_string': 'Mexiletine hydrochloride, Mexitil, Mexitil p.l.', 'drugSynonyms_string': 'KO 1173 CL, KO-1173, KO-1173 CL, KO-1173-CL, Katen, Mexiletine hcl, Mexiletine hydrochloride, NSC-758639', 'linkedDiseasesDrug_string': 'Ventricular Arrhythmia (HP_0004308), Peripheral Nervous System Disease (EFO_0009387)', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1202 | Q17 | What gene does the drug Aliskiren target? | The drug Aliskiren targets the gene REN. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%aliskiren%" OR LOWER(tradeNames_string) LIKE "%aliskiren%" OR LOWER(drugSynonyms_string) LIKE "%aliskiren%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2731', 'drugName': 'Aliskiren', 'tradeNames_string': 'Rasilez', 'drugSynonyms_string': 'Aliskiren, SPP-100, SPP100', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Essential Hypertension (MONDO_0001134), Iga Glomerulonephritis (EFO_0004194), Atrial Fibrillation (EFO_0000275), Congestive Heart Failure (EFO_0000373), Left Ventricular Hypertrophy (EFO_0003896), Coronary Atherosclerosis (MONDO_0021661), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Acute Coronary Syndrome (EFO_0005672), Stroke (EFO_0000712), Myocardial Infarction (EFO_0000612), Marfan Syndrome (MONDO_0007947), Chronic Kidney Disease (EFO_0003884), Diabetic Nephropathy (EFO_0000401), Heart Failure (EFO_0003144), Kidney Disease (EFO_0003086), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914)', 'yearOfFirstApproval': 2007, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'REN (ENSG00000143839)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4221', 'drugName': 'Aliskiren Fumarate', 'tradeNames_string': 'Tekturna', 'drugSynonyms_string': 'Aliskiren fumarate, Aliskiren hemifumarate, NSC-759185, SPP-100B, SPP100', 'linkedDiseasesDrug_string': 'Stroke (EFO_0000712), Hypertension (EFO_0000537)', 'yearOfFirstApproval': 2007, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'REN (ENSG00000143839)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1631 | Q17 | What gene does the drug Oxyphenonium target? | The drug Oxyphenonium targets 2 genes: CHRM1 and CHRM3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%oxyphenonium%" OR LOWER(tradeNames_string) LIKE "%oxyphenonium%" OR LOWER(drugSynonyms_string) LIKE "%oxyphenonium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1721', 'drugName': 'Oxyphenonium', 'tradeNames_string': '', 'drugSynonyms_string': 'Oxyphenonium, Oxyphenonium cation, Oxyphenonium ion', 'linkedDiseasesDrug_string': 'Gastrointestinal Disease (EFO_0010282)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1720', 'drugName': 'Oxyphenonium', 'tradeNames_string': '', 'drugSynonyms_string': 'Oxyphenonium, Oxyphenonium cation, Oxyphenonium ion', 'linkedDiseasesDrug_string': 'Gastrointestinal Disease (EFO_0010282)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1164', 'drugName': 'Oxyphenonium Bromide', 'tradeNames_string': 'Antrenyl', 'drugSynonyms_string': 'Antrenil, BA-5473, C-5473, NSC-759248, Oxifenon, Oxyfenon, Oxyphenon, Oxyphenonium bromide, Spasmodin, Spasmophen', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1163', 'drugName': 'Oxyphenonium Bromide', 'tradeNames_string': 'Antrenyl', 'drugSynonyms_string': 'Antrenil, BA-5473, C-5473, NSC-759248, Oxifenon, Oxyfenon, Oxyphenon, Oxyphenonium bromide, Spasmodin, Spasmophen', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.506 | Q17 | What gene does the drug N6022 target? | The drug N6022 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene ADH5. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%n6022%" OR LOWER(tradeNames_string) LIKE "%n6022%" OR LOWER(drugSynonyms_string) LIKE "%n6022%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4985', 'drugName': 'N6022', 'tradeNames_string': '', 'drugSynonyms_string': 'N-6022, N6022', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Cystic Fibrosis (MONDO_0009061)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'ADH5 (ENSG00000197894)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1670 | Q17 | What gene does the drug Cafusertib target? | The drug Cafusertib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene PLK1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cafusertib%" OR LOWER(tradeNames_string) LIKE "%cafusertib%" OR LOWER(drugSynonyms_string) LIKE "%cafusertib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2649', 'drugName': 'Cafusertib', 'tradeNames_string': '', 'drugSynonyms_string': 'Cafusertib', 'linkedDiseasesDrug_string': 'Acute Myeloid Leukemia (EFO_0000222), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'PLK1 (ENSG00000166851)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.182 | Q17 | What gene does the drug Carbenoxolone target? | The drug Carbenoxolone targets 2 genes: HSD11B2 and HSD11B1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%carbenoxolone%" OR LOWER(tradeNames_string) LIKE "%carbenoxolone%" OR LOWER(drugSynonyms_string) LIKE "%carbenoxolone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5312', 'drugName': 'Carbenoxolone', 'tradeNames_string': '', 'drugSynonyms_string': 'Carbenoxolone', 'linkedDiseasesDrug_string': 'Peptic Ulcer (HP_0004398), Gastroesophageal Reflux Disease (EFO_0003948)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HSD11B2 (ENSG00000176387), HSD11B1 (ENSG00000117594)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1419 | Q17 | What gene does the drug Hydrocortisone target? | The drug Hydrocortisone targets the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%hydrocortisone%" OR LOWER(tradeNames_string) LIKE "%hydrocortisone%" OR LOWER(drugSynonyms_string) LIKE "%hydrocortisone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2255', 'drugName': 'Prednisone', 'tradeNames_string': 'Cortan, Cortancyl, Decortisyl, Delta-dome, Deltasone, Fernisone, Liquid pred, Lodotra, Meticorten, Orasone, Paracort, Prednicen-m, Prednisone, Prednisone intensol, Rayos, Servisone, Sterapred', 'drugSynonyms_string': '3en3hg4wsw, Decortin, Dehydrocortisone, Metacortandracin, NSC-10023, Prednisone, Prednisone anhydrous, Prednisone tablets, Supercortil', 'linkedDiseasesDrug_string': "Psoriasis (EFO_0000676), Multiple Myeloma (EFO_0001378), Ankylosing Spondylitis (EFO_0003898), Essential Thrombocythemia (EFO_0000479), Lymphoplasmacytic Lymphoma (MONDO_0000432), Hemophagocytic Syndrome (MONDO_0015540), Vasculitis (EFO_0006803), Iga Glomerulonephritis (EFO_0004194), Igg4-Related Retroperitoneal Fibrosis (MONDO_0018848), Allergic Rhinitis (EFO_0005854), Lung Disease (EFO_0003818), Iridocyclitis (HP_0001094), Eosinophilic Pneumonia (EFO_0007257), Temporal Arteritis (EFO_1001209), Graves Ophthalmopathy (EFO_1001466), Sciatica (HP_0011868), Pemphigus Vulgaris (EFO_0004719), Seasonal Allergic Rhinitis (EFO_0003956), Dermatitis Herpetiformis (EFO_1000684), Atopic Eczema (EFO_0000274), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Hearing Loss (EFO_0004238), Hypereosinophilic Syndrome (EFO_1001467), Aplastic Anemia (HP_0001915), Granulomatosis With Polyangiitis (EFO_0005297), Keratitis (EFO_0009449), Nasal Cavity Polyp (EFO_1000391), Primary Adrenal Insufficiency (MONDO_0015128), Optic Neuritis (EFO_0007405), Viral Pneumonia (EFO_0007541), Hemangioma (EFO_1000635), Castleman Disease (MONDO_0015564), Hemolytic Anemia (EFO_0005558), Thymus Neoplasm (EFO_0002626), T-Lymphoblastic Lymphoma (MONDO_0044917), Choroiditis (MONDO_0001280), Gout (EFO_0004274), Iritis (EFO_1000997), Heart Disease (EFO_0003777), Follicular Lymphoma (MONDO_0018906), Chronic Inflammatory Demyelinating Polyneuropathy (EFO_0009538), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Churg-Strauss Syndrome (EFO_0007208), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Lymphoma, Aids-Related (EFO_1001365), Classic Hodgkin Lymphoma (MONDO_0009348), Autoimmune Hepatitis (EFO_0005676), Takayasu Arteritis (EFO_1001857), Adrenocortical Insufficiency (EFO_0009491), Kidney Disease (EFO_0003086), Myocarditis (EFO_0009609), Adult T-Cell Leukemia/Lymphoma (MONDO_0019471), Thrombotic Thrombocytopenic Purpura (MONDO_0018896), Stevens-Johnson Syndrome (EFO_0004276), Lupus Nephritis (EFO_0005761), Cancer (MONDO_0004992), Fanconi Anemia (MONDO_0019391), Non-Hodgkins Lymphoma (EFO_0005952), Opsoclonus-Myoclonus Syndrome (EFO_1001383), Chronic Lymphocytic Leukemia (EFO_0000095), Multiple Sclerosis (MONDO_0005301), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Juvenile Dermatomyositis (EFO_0000557), Pain (EFO_0003843), Sympathetic Ophthalmia (EFO_1001205), Neuromyelitis Optica (EFO_0004256), Anaplastic Large Cell Lymphoma (EFO_0003032), Pulmonary Tuberculosis (EFO_1000049), Gastrointestinal Stromal Tumor (MONDO_0011719), Myelodysplastic Syndrome (EFO_0000198), Leber Congenital Amaurosis (MONDO_0018998), Autoimmune Disease (EFO_0005140), Urticaria (EFO_0005531), Prostate Carcinoma (EFO_0001663), Classic Congenital Adrenal Hyperplasia Due To 21-Hydroxylase Deficiency (MONDO_0008728), Uveitis (EFO_1001231), Hepatocellular Carcinoma (EFO_0000182), Congestive Heart Failure (EFO_0000373), Mantle Cell Lymphoma (EFO_1001469), Gangliosidosis (MONDO_0017719), Myelofibrosis (MONDO_0044903), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Acute Lymphoblastic Leukemia (EFO_0000220), Vestibular Neuronitis (EFO_0007537), Acute Myeloid Leukemia (EFO_0000222), Hemophilia A (MONDO_0010602), Polymyalgia Rheumatica (EFO_0008518), Dermatomyositis (EFO_0000398), Diffuse Large B-Cell Lymphoma (EFO_0000403), Allergic Conjunctivitis (EFO_0007141), Sinusitis (EFO_0007486), Asthma (MONDO_0004979), Anemia, Hemolytic, Autoimmune (EFO_1001264), Duchenne Muscular Dystrophy (MONDO_0010679), Hodgkins Lymphoma (EFO_0000183), Mature T-Cell And Nk-Cell Non-Hodgkin Lymphoma (MONDO_0000430), Chronic Kidney Disease (EFO_0003884), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Hiv Infection (EFO_0000764), Osteoarthritis (MONDO_0005178), Frontotemporal Dementia (MONDO_0017276), Myeloproliferative Disorder (EFO_0004251), Type Iii Hypersensitivity Reaction Disease (EFO_1001222), Non-Small Cell Lung Carcinoma (EFO_0003060), Posterior Uveitis (EFO_1001119), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211), Neuroblastoma (EFO_0000621), Alzheimer Disease (MONDO_0004975), Langerhans Cell Histiocytosis (EFO_1000318), Primary Myelofibrosis (EFO_0002430), Chorioretinitis (HP_0012424), Pure Red Cell Aplasia (HP_0012410), Oral Lichen Planus (EFO_0008517), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Bell'S Palsy (EFO_0007167), Aids (EFO_0000765), Idiopathic Pulmonary Fibrosis (EFO_0000768), Focal Segmental Glomerulosclerosis (EFO_0004236), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131), Hepatitis, Alcoholic (EFO_1001345), Deafness (EFO_0001063), Breast Cancer (MONDO_0007254), Juvenile Idiopathic Arthritis (EFO_0002609), Psoriatic Arthritis (EFO_0003778), Arthritis (EFO_0005856), Lymphoma (EFO_0000574), Frozen Shoulder (EFO_1000941), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Mycosis Fungoides (EFO_1001051), Tenosynovitis (EFO_1001435), Hypercalcemia (HP_0003072), Exfoliative Dermatitis (EFO_0009456), Microscopic Polyangiitis (EFO_1000784), Central Nervous System Neoplasm (EFO_1000158), Contact Dermatitis (EFO_0005319), Abnormality Of Blood And Blood-Forming Tissues (HP_0001871), Intermediate Uveitis (EFO_1000986), Pulmonary Sarcoidosis (DOID_13406), Neoplasm Of Mature B-Cells (EFO_0000096), Rhinitis, Allergic, Perennial (EFO_1001417), Respiratory Syncytial Virus Infection (EFO_1001413), Chronic Obstructive Pulmonary Disease (EFO_0000341), Allergic Disease (MONDO_0005271), Erythema Multiforme (EFO_1000694), Chronic Myeloproliferative Disorder (EFO_0002428), Sarcoidosis (MONDO_0019338), Pemphigus (EFO_1000749), Ophthalmic Herpes Zoster (EFO_0007403), Berylliosis (EFO_0007168), Neoplasm (EFO_0000616), Heart Failure (EFO_0003144), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Tuberculosis (MONDO_0018076), Seborrheic Dermatitis (EFO_1000764), Interstitial Nephritis (MONDO_0001085), Pulmonary Fibrosis (EFO_0009448), Type 2 Diabetes Mellitus (MONDO_0005148), Anti-Neutrophil Antibody Associated Vasculitis (EFO_0004826), Lymphoproliferative Syndrome (MONDO_0016537), Canavan Disease (MONDO_0010079), Lateral Epicondylitis (EFO_1001896), Esophageal Stricture (HP_0002043), Pneumonia (EFO_0003106), Graft Versus Host Disease (MONDO_0013730), Covid-19 (MONDO_0100096), Hiv-Associated Nephropathy (EFO_0007313), Systemic Lupus Erythematosus (MONDO_0007915), Burkitts Lymphoma (EFO_0000309), Myasthenia Gravis (EFO_0004991), Angioimmunoblastic T-Cell Lymphoma (EFO_0000255), Ulcerative Colitis (EFO_0000729), B-Cell Neoplasm (MONDO_0004095), Gaucher Disease (MONDO_0018150), Polycythemia Vera (EFO_0002429), Gaucher Disease Type 2 (Orphanet_77260), Prostate Adenocarcinoma (EFO_0000673), Nephrotic Syndrome (EFO_0004255), Hepatitis C Virus Infection (EFO_0003047), Henoch-Schoenlein Purpura (EFO_1000965), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Stiff-Person Syndrome (EFO_0007498), Bullous Pemphigoid (EFO_0007187), Parkinson Disease (MONDO_0005180), Glucose Intolerance (HP_0001952), Acute Graft Vs. Host Disease (EFO_0004599), Polymyositis (EFO_0003063), Membranous Glomerulonephritis (EFO_0004254), Thrombocytopenia (HP_0001873), Synovitis (EFO_0008997), Lymphoblastic Lymphoma (MONDO_0000873), Soft Tissue Sarcoma (EFO_1001968), Inflammation (MP_0001845), Rheumatoid Arthritis (EFO_0000685), Meningeal Tuberculosis (EFO_1000039), Subacute Thyroiditis (EFO_1001194), Cardiomyopathy (EFO_0000318), Igg4-Related Disease (MONDO_0017287), Lymphoid Leukemia (EFO_0004289), Cholesterol Embolism (EFO_0005801), Amyotrophic Lateral Sclerosis (MONDO_0004976), Trichinosis (EFO_0007520), Sensorineural Hearing Loss (EFO_1001176), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Cystic Fibrosis (MONDO_0009061)", 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5998', 'drugName': 'Hydrocortisone Phosphoric Acid', 'tradeNames_string': '', 'drugSynonyms_string': 'Hydrocortisone phosphate', 'linkedDiseasesDrug_string': 'Hemorrhoid (EFO_0009552), Eye Inflammation (EFO_0005752)', 'yearOfFirstApproval': 1960, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1914', 'drugName': 'Hydrocortisone Valerate', 'tradeNames_string': 'Hydrocortisone valerate, Westcort', 'drugSynonyms_string': 'Cortisol 17-valerate, Hydrocortisone 17-valerate, Hydrocortisone valerate, NSC-759133', 'linkedDiseasesDrug_string': 'Hemorrhoid (EFO_0009552), Eye Inflammation (EFO_0005752)', 'yearOfFirstApproval': 1978, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3811', 'drugName': 'Hydrocortisone Butyrate', 'tradeNames_string': 'Hydrocortisone butyrate, Locoid, Locoid c, Locoid crelo, Locoid lipocream', 'drugSynonyms_string': 'Cortisol 17-butyrate, Hydrocortisone 17-butyrate, Hydrocortisone butyrate, Hydrocortisone-17-butyrate, NSC-758433', 'linkedDiseasesDrug_string': 'Atopic Eczema (EFO_0000274), Seborrheic Dermatitis (EFO_1000764), Skin Disease (EFO_0000701), Psoriasis Vulgaris (EFO_1001494)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5987', 'drugName': 'Hydrocortisone Sodium Phosphate', 'tradeNames_string': 'Efcortesol, Hydrocortone', 'drugSynonyms_string': 'Cortisol 21-(disodium phosphate), Hydrocortisone sodium phosphate', 'linkedDiseasesDrug_string': 'Hemorrhoid (EFO_0009552), Eye Inflammation (EFO_0005752)', 'yearOfFirstApproval': 1960, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1752', 'drugName': 'Hydrocortisone Hemisuccinate', 'tradeNames_string': '', 'drugSynonyms_string': 'Hydrocortisone Hemisuccinate, Hydrocortisone succinate, NSC-757049, NSC-7576', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Leukemia (EFO_0000565), Septic Shock (EFO_0006834), Hemorrhoid (EFO_0009552), Eye Inflammation (EFO_0005752), Acute Lymphoblastic Leukemia (EFO_0000220), Anaplastic Large Cell Lymphoma (EFO_0003032), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Burkitts Lymphoma (EFO_0000309), Diffuse Large B-Cell Lymphoma (EFO_0000403)', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1708', 'drugName': 'Hydrocortisone', 'tradeNames_string': 'Acetasol hc, Acticort, Aeroseb-hc, Ala-cort, Ala-scalp, Alkindi sprinkle, Alphaderm, Anflam, Anucort-Hc, Anugesic hc, Anusol hc, Anusol plus hc, Anusol soothing relief, Anusol-Hc, Balneol-hc, Beta-hc, Calmurid hc, Canesten hc, Cetacort, Cipro hc, Cobadex, Colocort, Corlan, Cort-dome, Cortef, Cortenem, Cortenema, Cortril, Daktacort, Daktacort hydrocort, Derma care hydrocort, Dermacort, Dermaspray demang, Dioderm, Dome-cort, Econacort, Efcortelan p, Eldecort, Epicort, Eurax-hc, Eurax-hydrocort, Evacort, Exe-cort, Flexicort, Germoloids hc, Glycort, Gregoderm, H-cort, Hc #1, Hc #4, Hc (hydrocortisone), Hi-cor, Hydro-rx, Hydrocort in calamine oily, Hydrocort in cetomacrogol for a, Hydrocort in wte soft paraf, Hydrocortisone, Hydrocortisone in absorbase, Hydrocortone, Hydroderm, Hydroderm hc, Hytone, Jungle for, Locoid, Medicort, Mildison lipocream, Nogenic hc, Nutracort, Nybadex, Nystaform-hc, Otoseptil, Otosporin, Penecort, Perinal, Plenadren, Proctocort, Proctocream hc, Proctofoam hc, Proctosedyl, Quinocort, Sential hc, Stie-cort, Synacort, Terra-cortril nystatin, Texacort, Timocort, Timodine, Topisone, Tri-cicatrin, Uniroid, Uniroid hc, Xyloproct, Zenoxone', 'drugSynonyms_string': 'Cor-Oticin, Cortifoam, Cortisol, FLEXICORT, Hydrocortisone, Micort-HC, NSC-10483, Neo-Cortef, Ophthocort, Terra-Cortril, U-Cort', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Infection (EFO_0000544), Hemophagocytic Syndrome (MONDO_0015540), Chronic Primary Adrenal Insufficiency (MONDO_0015129), Refractory Anemia (EFO_0003802), Acute Myelomonocytic Leukemia (EFO_0000223), Atopic Eczema (EFO_0000274), Congenital Adrenal Hyperplasia (MONDO_0018479), Acute Myeloblastic Leukemia Without Maturation (EFO_0003027), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Acute Leukemia Of Ambiguous Lineage (MONDO_0019460), Primary Adrenal Insufficiency (MONDO_0015128), Viral Pneumonia (EFO_0007541), Borderline Personality Disorder (HP_0012076), Alopecia Areata (EFO_0004192), Acute Erythroleukemia (EFO_0000218), Leukemia (EFO_0000565), Adrenocortical Insufficiency (EFO_0009491), Cancer (MONDO_0004992), Obesity (EFO_0001073), Anaplastic Large Cell Lymphoma (EFO_0003032), Hypotension (EFO_0005251), Myelodysplastic Syndrome (EFO_0000198), Aging (GO_0007568), Classic Congenital Adrenal Hyperplasia Due To 21-Hydroxylase Deficiency (MONDO_0008728), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Allergic Conjunctivitis (EFO_0007141), Memory Impairment (EFO_0001072), Asthma (MONDO_0004979), Insulin Resistance (EFO_0002614), Hemorrhoid (EFO_0009552), Influenza (EFO_0007328), Opioid Dependence (EFO_0005611), Pancreatitis (EFO_0000278), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Hiv Infection (EFO_0000764), Osteoarthritis (MONDO_0005178), Myeloproliferative Disorder (EFO_0004251), Acute Monocytic Leukemia (EFO_0000221), Dermatitis (MONDO_0002406), Mast-Cell Leukemia (EFO_0007359), Psoriasis Vulgaris (EFO_1001494), Atrial Fibrillation (EFO_0000275), Herpes Labialis (EFO_1001347), Lymphoma (EFO_0000574), Fibromyalgia (EFO_0005687), Acute Megakaryoblastic Leukaemia (EFO_0003025), Central Nervous System Neoplasm (EFO_1000158), Myocardial Infarction (EFO_0000612), Alcohol Dependence (MONDO_0007079), Eczema (HP_0000964), Opioid Use Disorder (EFO_0010702), Heart Failure (EFO_0003144), Type 1 Diabetes Mellitus (MONDO_0005147), Phobic Disorder (EFO_1001908), Pneumonia (EFO_0003106), Covid-19 (MONDO_0100096), Otitis Externa (EFO_0009560), Injury (EFO_0000546), Ulcerative Colitis (EFO_0000729), Prostate Adenocarcinoma (EFO_0000673), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Nicotine Dependence (EFO_0003768), Septic Shock (EFO_0006834), Eye Inflammation (EFO_0005752), Chronic Myelomonocytic Leukemia (EFO_1001779), Cardiac Arrest (EFO_0009492), Refractory Anemia With Excess Blasts (EFO_0003811), Sepsis (HP_0100806), Lymphoblastic Lymphoma (MONDO_0000873), Inflammation (MP_0001845), Nasal Congestion (HP_0001742), Adrenal Cortex Carcinoma (EFO_1000796), Melanoma (EFO_0000756), Bronchopulmonary Dysplasia (MONDO_0019091), Oral Submucous Fibrosis (EFO_1001818), Hypoxia (EFO_0009444), Cirrhosis Of Liver (EFO_0001422)", 'yearOfFirstApproval': 1952, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_71', 'drugName': 'Hydrocortisone Acetate', 'tradeNames_string': 'Barquinol hc, Chloromycetin hydrocort, Colifoam, Cortef acetate, Cortifoam, Cortril, Cortucid, Dricort, Epifoam, Framycort, Fucidin h, Genticin hc, Gentisone hc, Gppe ear susp, Gppe eye crm, Gppe foam aero, Hc45 hydrocort, Hemsol-hc, Hepacort plus, Hydrocal, Hydrocortisone acetate, Hydrocortone, Lanacort, Micort-hc, Neo-cortef, Orabase hca', 'drugSynonyms_string': 'Cortisol 21-acetate, Hydrocortisone 21-acetate, Hydrocortisone Acetate, Hydrocortisone acetate, Hydrocortisoni acetas, NSC-741', 'linkedDiseasesDrug_string': 'Vitiligo (EFO_0004208), Hemorrhoid (EFO_0009552), Eye Inflammation (EFO_0005752), Atopic Eczema (EFO_0000274), Inflammation (MP_0001845), Skin Disease (EFO_0000701), Depressive Disorder (MONDO_0002050), Pruritus (HP_0000989)', 'yearOfFirstApproval': 1951, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2728', 'drugName': 'Hydrocortisone Probutate', 'tradeNames_string': 'Pandel', 'drugSynonyms_string': 'Hydrocortisone buteprate, Hydrocortisone butyrate propionate, Hydrocortisone probutat, Hydrocortisone probutate, TS 408, TS-408', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Cancer (MONDO_0004992), Ulcerative Colitis (EFO_0000729), Endocrine System Disease (EFO_0001379), Juvenile Idiopathic Arthritis (EFO_0002609), Bursitis (MONDO_0002471), Atopic Eczema (EFO_0000274), Psoriatic Arthritis (EFO_0003778), Adrenal Gland Disease (EFO_0005539), Lymphoma (EFO_0000574), Tenosynovitis (EFO_1001435), Pruritus (HP_0000989), Exanthem (EFO_1000697), Allergic Conjunctivitis (EFO_0007141), Asthma (MONDO_0004979), Inflammation (MP_0001845), Rheumatoid Arthritis (EFO_0000685), Osteoarthritis (MONDO_0005178), Leukemia (EFO_0000565), Type Iii Hypersensitivity Reaction Disease (EFO_1001222), Seborrheic Dermatitis (EFO_1000764), Skin Disease (EFO_0000701), Spondylitis (MONDO_0003937), Dermatitis (MONDO_0002406)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2729', 'drugName': 'Hydrocortisone Cypionate', 'tradeNames_string': 'Cortef', 'drugSynonyms_string': 'Hydrocortisone Cypionate, Hydrocortisone cipionate, Hydrocortisone cyclopentylpropionate, Hydrocortisone cypionate, NSC-10721', 'linkedDiseasesDrug_string': 'Chronic Primary Adrenal Insufficiency (MONDO_0015129), Hemorrhoid (EFO_0009552), Eye Inflammation (EFO_0005752)', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1393', 'drugName': 'Fludrocortisone Acetate', 'tradeNames_string': 'Astonin, Florinef, Fludrocortisone acetate, Fludrocortone, Panotile', 'drugSynonyms_string': 'Fludrocortisone 21-acetate, Fludrocortisone acetate, Fludrocortisoni acetas, Fluorhydrocortisone acetate, Fluorocortisol acetate, NSC-15186, Scherofluron', 'linkedDiseasesDrug_string': 'Primary Adrenal Insufficiency (MONDO_0015128), Septic Shock (EFO_0006834), Sensorineural Hearing Loss (EFO_1001176), Congenital Adrenal Hyperplasia (MONDO_0018479), Covid-19 (MONDO_0100096), Parkinson Disease (MONDO_0005180), Melanoma (EFO_0000756), Chronic Primary Adrenal Insufficiency (MONDO_0015129), Ovarian Hyperstimulation Syndrome (MONDO_0011972), Depressive Disorder (MONDO_0002050), Adrenogenital Syndrome (MONDO_0015898), Severe Acute Respiratory Syndrome (EFO_0000694)', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C2 (ENSG00000151623)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1162', 'drugName': 'Hydrocortisone Sodium Succinate', 'tradeNames_string': 'A-hydrocort, Hcss, Hydrocortisone sodium succinate, Solu-cortef', 'drugSynonyms_string': 'Cortisol 21-(sodium succinate), Hydrocortisone 21-sodium succinate, Hydrocortisone sodium succinate, Hydrocortisoni natrii succinas, NSC-9152, SOLU-CORTEF', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Leukemia (EFO_0000565), Septic Shock (EFO_0006834), Hemorrhoid (EFO_0009552), Eye Inflammation (EFO_0005752), Acute Lymphoblastic Leukemia (EFO_0000220), Anaplastic Large Cell Lymphoma (EFO_0003032), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Burkitts Lymphoma (EFO_0000309), Diffuse Large B-Cell Lymphoma (EFO_0000403)', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1014 | Q17 | What gene does the drug Dicyclomine Hydrochloride target? | The drug Dicyclomine Hydrochloride targets 2 genes: CHRM1 and CHRM3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dicyclomine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%dicyclomine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%dicyclomine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2299', 'drugName': 'Dicyclomine Hydrochloride', 'tradeNames_string': 'Bentyl, Bentyl preservative free, Dicyclomine Hydrochloride (Preservative-Free), Dicyclomine hydrochloride, Dicyclomine hydrochloride (preservative free), Merbentyl, Merbentyl 20', 'drugSynonyms_string': 'Bentylol, Dicyclomine hcl, Dicyclomine hydrochloride, Dicycloverine hydrochloride, Kolantyl hydrochloride, NSC-404381, Wyovin', 'linkedDiseasesDrug_string': 'Irritable Bowel Syndrome (EFO_0000555)', 'yearOfFirstApproval': 1950, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2300', 'drugName': 'Dicyclomine Hydrochloride', 'tradeNames_string': 'Bentyl, Bentyl preservative free, Dicyclomine Hydrochloride (Preservative-Free), Dicyclomine hydrochloride, Dicyclomine hydrochloride (preservative free), Merbentyl, Merbentyl 20', 'drugSynonyms_string': 'Bentylol, Dicyclomine hcl, Dicyclomine hydrochloride, Dicycloverine hydrochloride, Kolantyl hydrochloride, NSC-404381, Wyovin', 'linkedDiseasesDrug_string': 'Irritable Bowel Syndrome (EFO_0000555)', 'yearOfFirstApproval': 1950, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1978 | Q17 | What gene does the drug Minaprine Hydrochloride target? | The drug Minaprine Hydrochloride targets 8 genes: HTR2A, HTR2B, CHRM1, DRD2, HTR2C, MAOA, ACHE and DRD1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%minaprine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%minaprine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%minaprine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4774', 'drugName': 'Minaprine Hydrochloride', 'tradeNames_string': 'Cantor', 'drugSynonyms_string': '30038-CB, 30038CB, Minaprine dihydrochloride, Minaprine hcl, Minaprine hydrochloride, NSC-305742', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD1 (ENSG00000184845), CHRM1 (ENSG00000168539), ACHE (ENSG00000087085), MAOA (ENSG00000189221), HTR2B (ENSG00000135914), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246)', 'numberLinkedTargets': 8}, {'UUID': 'DrugGeneTargets_v2_4771', 'drugName': 'Minaprine Hydrochloride', 'tradeNames_string': 'Cantor', 'drugSynonyms_string': '30038-CB, 30038CB, Minaprine dihydrochloride, Minaprine hcl, Minaprine hydrochloride, NSC-305742', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD1 (ENSG00000184845), CHRM1 (ENSG00000168539), ACHE (ENSG00000087085), MAOA (ENSG00000189221), HTR2B (ENSG00000135914), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246)', 'numberLinkedTargets': 8}, {'UUID': 'DrugGeneTargets_v2_4772', 'drugName': 'Minaprine Hydrochloride', 'tradeNames_string': 'Cantor', 'drugSynonyms_string': '30038-CB, 30038CB, Minaprine dihydrochloride, Minaprine hcl, Minaprine hydrochloride, NSC-305742', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD1 (ENSG00000184845), CHRM1 (ENSG00000168539), ACHE (ENSG00000087085), MAOA (ENSG00000189221), HTR2B (ENSG00000135914), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246)', 'numberLinkedTargets': 8}, {'UUID': 'DrugGeneTargets_v2_4775', 'drugName': 'Minaprine Hydrochloride', 'tradeNames_string': 'Cantor', 'drugSynonyms_string': '30038-CB, 30038CB, Minaprine dihydrochloride, Minaprine hcl, Minaprine hydrochloride, NSC-305742', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD1 (ENSG00000184845), CHRM1 (ENSG00000168539), ACHE (ENSG00000087085), MAOA (ENSG00000189221), HTR2B (ENSG00000135914), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246)', 'numberLinkedTargets': 8}, {'UUID': 'DrugGeneTargets_v2_4773', 'drugName': 'Minaprine Hydrochloride', 'tradeNames_string': 'Cantor', 'drugSynonyms_string': '30038-CB, 30038CB, Minaprine dihydrochloride, Minaprine hcl, Minaprine hydrochloride, NSC-305742', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD1 (ENSG00000184845), CHRM1 (ENSG00000168539), ACHE (ENSG00000087085), MAOA (ENSG00000189221), HTR2B (ENSG00000135914), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246)', 'numberLinkedTargets': 8}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.864 | Q17 | What gene does the drug Lh (Menotropins) target? | The drug Lh (Menotropins) targets the gene LHCGR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lh (menotropins)%" OR LOWER(tradeNames_string) LIKE "%lh (menotropins)%" OR LOWER(drugSynonyms_string) LIKE "%lh (menotropins)%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1661', 'drugName': 'Lh (Menotropins)', 'tradeNames_string': '', 'drugSynonyms_string': 'Human lh, Lh (menotropins)', 'linkedDiseasesDrug_string': 'Infertility (EFO_0000545)', 'yearOfFirstApproval': 1975, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'LHCGR (ENSG00000138039)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.